Drugs and Drug Candidates doi: 10.3390/ddc5020032

Authors: Monserrat Hernández-Morales Sergio Alcalá-Alcalá Luis Arias-Durán Jaime Escalante-García Jorge Alberto Barrios-Payán Rogelio Hernández-Pando Samuel Estrada-Soto

Background/Objectives: Achillea millefolium is a well-known plant used in traditional medicine for the treatment of inflammation, gastrointestinal disorders, respiratory diseases, hypertension, and diabetes, among others. These effects are attributed to the metabolite content of flavonoids and terpenes such as achillin (1) and leucodin (2). Thus, the current investigation aims to standardize the extracts from A. millefollium based on the presence of 1 and 2 and relate them to their relaxant effect in ex vivo assays. Methods: A validated High-Performance Liquid Chromatography (HPLC) method was used to determine the concentration of the main compounds, employing standard molecules previously isolated from the same species and characterized by nuclear magnetic resonance (NMR) and X-ray diffraction. Also, the relaxant effects of both compounds and their combinations were assayed on aortic and tracheal rat rings in an organ bath. Results: Compounds (1) and (2) are the main compounds in hexane, dichloromethane, and hydroalcoholic extracts, present in different proportions. The relaxant effects in ex vivo models of the aorta and trachea showed that the sesquiterpene lactones achillin (1) [Trachea, maximum effect (Emax): 67.67 ± 5.01%, medium effective concentration (EC50): 304.44 ± 2.61 µM; Aorta: Emax: 63.94 ± 6.28%, EC50: 225.73 ± 4.49 µM)] and leucodin (2) (Trachea: Emax: 76.71 ± 4.73%, EC50: 266.40 ± 2.05 µM; Aorta, Emax: 72.96 ± 1.73%, EC50: 163.29 ± 2.99 µM) are responsible for the relaxant effects shown by the extracts. The observed effect is proportional to the concentration of these molecules, with hexane extracts being more active. Additionally, we demonstrate the safety of molecules 1 and 2 through toxicological studies recommended by the OECD. Conclusions: The isolated compounds achillin and leucodin are the primary constituents in the flowers of A. millefolium, with higher concentrations found in hexane extracts, particularly of achillin, which shows a correlation of 2.33 with respect to leucodin. This correlation is closely related to their relaxant effect, as these compounds are the main contributors to the relaxant response in the trachea and aorta, being more effective when used together.

Drugs and Drug Candidates doi: 10.3390/ddc5020031

Authors: María Eugenia Acevedo Judith Anna Roether Sofía Harriet Adriana Fernández Juan Pablo Cattalini Héctor Juan Prado Aldo R. Boccaccini Viviana Mouriño

Background/Objectives: A matrix system for topical application was developed for a hydrophobic drug model, benzoyl peroxide (BPO), by turning it into its amorphous state to increase its bioavailability. BPO is commonly used to treat acne vulgaris; however, the commercially available products possess several drawbacks including poor absorption due to large crystal size and thus reduced efficacy and skin irritation. Methods: Several polymeric films containing amorphous BPO were successfully prepared for the first time from polymer + plasticizer colloidal dispersions and characterized. Results: The loaded BPO maintained its amorphous state even after 24 months of storage at 5 °C, and drug release could be modulated by adjusting the film compositions. The prepared films were obtained by solvent evaporation, and residual acetone remained below the level of quantification of the analytical method. In addition, the films were thin, flexible, transparent, bioadhesive, and able to remain on the skin for a clinically relevant period. Microscopic imaging confirmed a homogeneous and continuous morphology. Conclusions: The developed formulations may represent promising alternatives for the treatment of acne vulgaris.

Drugs and Drug Candidates doi: 10.3390/ddc5020030

Authors: Gabriel Tchuente Kamsu Eugene Jamot Ndebia

Background/Objectives: Oral cancer remains a major global health challenge, with persistent limitations in treatment efficacy and significant therapy-related morbidity. Probiotics, owing to their immunomodulatory, anti-inflammatory, and microbiota-regulating properties, have emerged as potential therapeutic and adjuvant agents. This scoping review aimed to systematically map and critically appraise preclinical and clinical evidence regarding the therapeutic and supportive effects of probiotics in oral cancer. Methods: A comprehensive literature search was conducted across PubMed, Scopus, Web of Science, and Google Scholar without temporal restrictions, including studies published up to February 2026. Eligible studies comprised in vitro, in vivo, and clinical investigations evaluating the effects of live or non-viable probiotic interventions on oral cancer biology and related clinical outcomes. Results: Twenty-one studies were included: 13 in vitro, 3 in vivo, and 6 clinical studies. Preclinical evidence indicates that strains such as Lactiplantibacillus plantarum, Lactobacillus acidophilus, and Lacticaseibacillus paracasei exert selective antiproliferative effects (up to 85% inhibition) via apoptosis induction, modulation of PTEN/MAPK and NF-κB signaling, and reduction in pro-inflammatory mediators. In vivo models demonstrated tumor growth suppression and improved survival without significant toxicity. Clinically, probiotics reduced treatment-induced oral mucositis, improved salivary function, and enhanced microbiota stability and patient-reported outcomes. However, evidence on direct oncological endpoints remains limited. Conclusions: Probiotics demonstrate biologically plausible, strain-specific antitumor and supportive effects, with the strongest evidence supporting their role as adjunctive agents, particularly in managing treatment-related complications. Further well-designed in vivo and clinical studies are required to define optimal strains, dosing strategies, and integration with standard oncologic treatments.

Drugs and Drug Candidates doi: 10.3390/ddc5020029

Authors: Alba V. Demesa-Castañeda David J. Pérez César Millán-Pacheco Armando Hernández-Mendoza Rodrigo Said Razo-Hernández

In the published version of this article [...]

Drugs and Drug Candidates doi: 10.3390/ddc5020028

Authors: Angélica R. Bravo Matías F. Cuevas Christian Erick Palavecino

Background/Objectives: Multidrug-resistant (MDR) Enterobacter spp. are critical pathogens within the ESKAPE group, frequently exhibiting resistance to carbapenems. Antimicrobial photodynamic therapy (aPDT) represents a promising non-antibiotic strategy to circumvent these resistance mechanisms. This scoping review aims to map the current evidence regarding the efficacy of aPDT in inactivating Enterobacter spp., identifying the most effective photosensitizers (PS), light parameters, and existing research gaps. Methods: A systematic search was performed across PubMed, Scopus, and Google Scholar (2013–2025) following PRISMA-ScR guidelines and registered on OSF. Studies were included if they evaluated aPDT against Enterobacter spp. (in vitro or in vivo) and provided quantitative data on microbial reduction. Data was extracted using a standardized charting form covering bacterial strains, PS type, light source, and viability reduction. The results from the eligible sources of evidence were synthesized narratively to address the review objectives. Results: Despite the clinical priority of Enterobacter, only seven studies met the eligibility criteria. Methylene Blue remains the most frequently studied PS, achieving reductions of 3–8 log10. Emerging evidence highlights the synergistic efficacy of monocationic chlorins and graphene-based nanomaterials in enhancing the bactericidal effect of light-based treatments. Notably, aPDT demonstrated the ability to inactivate carbapenemases, the bacterial enzymes responsible for carbapenem resistance. However, only two studies evaluated in vivo applications, primarily within dental settings. Conclusions: aPDT is a promising method against MDR Enterobacter spp. and bypasses traditional resistance mechanisms. However, the limited number of studies indicates a significant knowledge gap. Future research should focus on standardized in vivo protocols and the synergy between aPDT and conventional antibiotics to support clinical translation.

Drugs and Drug Candidates doi: 10.3390/ddc5020027

Authors: Leonardo da Rocha Sousa Nildomar Ribeiro Viana Renato Sampaio Mello Neto José Otávio Carvalho Sena de Almeida José Vinícius de Sousa França Emerson Iuri Rodrigues Queiroz Esmeralda Maria Lustosa Barros Ana Karolinne da Silva Brito Ana Victória da Silva Mendes Andressa Amorim dos Santos Fernanda Cerqueira Barroso Oliveira Débora Santos Lula Barros Massimo Lucarini Alessandra Durazzo Maria do Carmo de Carvalho e Martins Daniel Dias Rufino Arcanjo

Background: Diabetes mellitus is a metabolic disturbance characterized by chronic hyperglycemia, which stems from defective secretion and/or action of insulin. D-Limonene has been studied for the confirmation of its antidiabetic and antioxidant effects. This paper aims to investigate the antidiabetic and antioxidants effects of D-Limonene in an experimental model of DM1. Methods: Female Wistar rats (180–250g) received streptozotocin (STZ, 45 mg/kg) intraperitoneally. Animals with capillary glycemia ≥ 250 mg/dL were considered diabetic. D-Limonene at oral doses of 12.5 mg/kg, 25 mg/kg and 50 mg/kg was administered during 28-day treatment. Water and food intake, weight gain and capillary glycemia were evaluated. At the end of the treatment, the following biochemical parameters were assessed: serum glucose, HbA1c, urea, creatinine, AST, ALT, GGT, ALP and albumin. The oxidative stress markers were determined in plasma, erythrocytes, and aortic homogenates: malondialdehyde, nitrite, myeloperoxidase, superoxide dismutase and catalase. Results: D-Limonene (25 and 50 mg/kg) significantly reduced serum glucose, HbA1c, AST, ALT, GGT and ALP when compared to DC, as well as plasma MDA and nitrite concentrations. Interestingly, D-Limonene (25 and 50 mg/kg) decreased both plasma and aortic myeloperoxidase activities, as well as increased both erythrocytic and aortic catalase activities. Conclusions: These findings, besides a marked D-Limonene-induced hypoglycemic effect, pave the way for further studies comprising a multi-target treatment by providing benefits on hepatic and vascular complications related to the diabetic condition.

Drugs and Drug Candidates doi: 10.3390/ddc5020026

Authors: Vitória Leite Lages Lourdes Fernanda Godinho Alayanne Santos Guieiro Thais Trindade Bruna Oliveira Costa Joyce Mirlene Moreira Costa Ramona Ramalho de Souza Pereira Caíque Olegário Diniz e Magalhães Kinulpe Honorato-Sampaio

Background/Objectives: Vasomotor symptoms (hot flashes) affect 70–80% of menopausal women, significantly impairing quality of life. Current treatments include hormone therapy, which is contraindicated for many patients, and non-hormonal alternatives with limited efficacy or adverse effects. Cannabidiol (CBD), a non-psychoactive phytocannabinoid, has emerged as a potential therapeutic candidate due to its interaction with the endocannabinoid system. This study aimed to investigate whether a standardized Cannabis sativa extract containing isolated CBD attenuates heat dissipation in ovariectomized rats, a preclinical model of estrogen deficiency. Methods: Female Wistar rats were randomly assigned to sham-operated vehicle-treated (SHAM-V), ovariectomized vehicle-treated (OVX-V), or ovariectomized CBD-treated (OVX-CBD; 10 mg/kg/day, oral gavage) groups. Treatment began on postoperative day 2 and continued for 21 days. Tail-skin temperature, a surrogate marker of heat dissipation, was assessed by infrared thermography on day 14. Energy metabolism was evaluated by indirect calorimetry on day 21. Uterine weight was measured as a biomarker of estrogen depletion. Results: Ovariectomy significantly increased tail temperature compared to SHAM-V. CBD treatment completely prevented this effect, with OVX-CBD animals exhibiting thermographic profiles similar to SHAM-V. Uterine atrophy was not reversed by CBD. No differences in the calorimetry parameter were observed among groups. Conclusions: This study provides novel preclinical evidence that cannabidiol attenuates ovariectomy-induced heat dissipation in rats, without detectable effects on uterine weight or metabolic parameters. These findings suggest that CBD may represent a potential non-hormonal approach for the management of menopausal vasomotor symptoms; however, further studies are required to elucidate the underlying mechanisms and to determine its translational and clinical relevance.

Drugs and Drug Candidates doi: 10.3390/ddc5020025

Authors: François Marceau

Angiotensin-converting enzyme (ACE) inhibitors (ACEis) are one of the most successful drug classes for the treatment of hypertension and the prevention of its cardiovascular complications. ACE activates the pressor hormone angiotensin but also inactivates the vasodilator peptide bradykinin (BK). A rare side effect of ACEis, angioedema (AE), has been proposed to result from pro-inflammatory effects of BK. Novel considerations are offered in this debate: (1) the bradykinin B2 receptor antagonist icatibant has had an inconsistent effect on ACEi-associated AE, but its potency and duration of action are much inferior to those of a novel nonpeptide antagonist of this receptor, deucrictibant. (2) Tissue kallikrein (KLK-1) is an effective kininogenase, particularly abundant in the salivary glands, possibly related to orofacial presentation of ACEi-induced AE. (3) The strongly regulated human kinin B1 receptor, optimally responsive to Lys-des-Arg9-BK, is functionally compartmentalized with KLK-1 which produces Lys-BK from kininogens. Chronic treatment with ACEi drugs in laboratory animals induces the expression of vascular B1R that mediates vasodilation. Therefore, ACEi-AE may be largely or completely initiated by KLK-1. Inhibitors of this protease or combined antagonists of both kinin receptor subtypes may be useful for the management of this condition.

Drugs and Drug Candidates doi: 10.3390/ddc5020024

Authors: Damião Sampaio de Sousa João Miguel Lopes de Melo Lima Carminda Sandra Brito Salmito-Vanderley Emmanuel Silva Marinho

Background/Objectives: Curcumin derivatives have attracted interest due to their redox-modulating properties and potential applications in aquatic organisms, yet their molecular interactions and environmental safety remain insufficiently characterized. This study aimed to evaluate the redox-related molecular behavior and ecotoxicological profile of curcumin derivatives, with emphasis on their interaction with glutathione S-transferase from L. vannamei. Methods: Molecular docking and molecular dynamics simulations were performed to assess binding stability and interaction patterns between the derivatives and LvGSTmu. In parallel, computational predictions were used to estimate environmental persistence, bioaccumulation (BCF/BAF), and acute and chronic aquatic toxicity across multiple trophic levels. Results: Docking and dynamics analyses indicated stable ligand–protein interactions, particularly for CURNO, which showed favorable binding behavior without destabilizing the protein structure. Ecotoxicological predictions suggested low bioaccumulation potential and limited persistence for most derivatives, with CURH and CURNO showing higher sediment persistence. Toxicity responses varied by organism and exposure time but did not differ significantly among derivatives relative to curcumin. Conclusions: The derivatives retained redox-related molecular features while presenting an overall acceptable predicted environmental profile. CURNO emerged as a promising candidate, although its environmental behavior supports the need for further monitoring and experimental validation.

Drugs and Drug Candidates doi: 10.3390/ddc5010023

Authors: Milena Oliveira Andrade Moreira Karla Susanna Tavares Grangeiro Belém Janaina Esmeraldo Rocha Davi Ramalho Furtado Gildenia Alves de Araújo Ana Joyce Morais Bento Jessica Bezerra Maciel Jesyka Macêdo Guedes Jaiza Maria Lima Dias Henrique Douglas Melo Coutinho Francisco das Chagas Lima Pinto Emmanuel Silva Marinho Marcia Machado Marinho Alexandre Magno Rodrigues Teixeira Walter José Peláez Hélcio S. dos Santos

Background/Objectives: Hydrazones are organic compounds with the general structure R2C=NNHR1, distinguished by their versatility and modifiability, and are widely used in various applications due to their physicochemical and biological properties. They exhibit anticancer, anti-inflammatory, antibiofilm, and antibacterial activities. Antibiotic-resistant bacteria pose a serious public health threat, employing mechanisms such as enzymatic inactivation and efflux pumps. This study evaluated the antibacterial activity of the hydrazone HDZH1,4BENZ, a hydralazine-derived compound, as well as its potential adjuvant effect in combination with antibiotics against Staphylococcus aureus strains expressing efflux pumps. Methods: The strains used were 1199B (NorA efflux pump-expressing) and K2068 (MepA efflux pump-expressing). All assays were conducted using the broth microdilution method in Brain Heart Infusion (BHI) medium. Initially, the intrinsic antibacterial activity of the compound was determined. Subsequently, modulation assays were performed to evaluate its potential effect on efflux pump activity, with a standard efflux pump inhibitor included as a positive control. Results: Although HDZH1,4BENZ did not demonstrate significant direct antibacterial activity, the results indicate that this hydrazone exerts a notable inhibitory effect on the NorA (Norfloxacin resistance efflux pump A) and MepA (Multidrug efflux protein A) efflux pumps in S. aureus, thereby enhancing the efficacy of antibacterial agents. Conclusions: The activity of the hydrazone was comparable to that of chlorpromazine, suggesting that it may represent a promising alternative in the fight against antibiotic-resistant bacterial infections.

Drugs and Drug Candidates doi: 10.3390/ddc5010022

Authors: Tainá Pereira da Silva Oliveira Alan Kelbis Oliveira Lima Talita Pereira Gonçalves Isadora Florêncio Sônia Nair Báo Namuhell Oliveira da Silva Patrícia Albuquerque Ildinete Silva-Pereira Luís Alexandre Muehlmann

Background/Objectives: Optimizing synthesis parameters is essential to ensure the quality and stability of nanostructures. This study aimed to optimize the synthesis of selenium nanoparticles (SeNPs) by chemical reduction, using sodium selenite (Na2SeO3), ascorbic acid (AA), and polyvinyl alcohol (PVA) at different concentrations, volumes, and molar ratios. The effects of reduction time, purification steps, and variations in the concentration of the precursor and reducing agent, as well as in the volume of the stabilizer, on the characteristics of SeNPs were investigated to ensure their long-term stability, maintenance of their properties, and biological applicability. Methods: The SeNPs were analyzed by UV/Vis absorption spectroscopy, Dynamic Light Scattering (DLS), and Transmission Electron Microscopy (TEM), and were also evaluated for antifungal activity against the SC5314 strain of Candida albicans. Results/Conclusions: Monodisperse SeNPs were obtained under high concentrations of Na2SeO3 and AA, short reduction time, higher volumes of PVA (2–4 mL), and purification at 24.300× g, presenting a spherical morphology, hydrodynamic diameter of 137.0–171.7 nm, dry diameter of 20–120 nm, polydispersity index of 0.049–0.306, Zeta potential of −7.79 to −19.6 mV, and stability for up to 180 days. In the absence or presence of 1 mL of PVA, the SeNPs were predominantly amorphous. Regarding biological activity, the SeNPs did not exhibit antifungal activity under the experimental conditions in the tested strain. Together, this study provides a comprehensive update on the synthesis of SeNPs under different conditions and their stability over time, contributing to the consolidation of knowledge in the field.

Drugs and Drug Candidates doi: 10.3390/ddc5010021

Authors: Ertugrul Gunday Fatma Sezer Senol Deniz

Alzheimer’s disease is a progressive neurodegenerative disorder marked by cognitive decline, and its global prevalence is expected to increase substantially in the coming decades. This review examines current therapeutic approaches and explores the potential role of medicinal plants and natural products in the treatment and prevention of Alzheimer’s disease. This review examines the pathophysiology of Alzheimer’s disease, with particular emphasis on the cholinergic, amyloid, and tau hypotheses. It evaluates currently approved therapeutic approaches, including cholinesterase inhibitors and NMDA receptor antagonists, as well as emerging immunotherapies. In addition, this review provides a comprehensive analysis of the pharmacological properties of various medicinal plants and explores innovative drug delivery systems. Research reveals that while conventional drugs like donepezil and memantine provide symptomatic relief, they do not halt disease progression. Recent immunotherapies, including lecanemab and donanemab, show potential to reduce amyloid-beta accumulation and slow cognitive decline; however, they face safety concerns, such as amyloid-related imaging abnormalities, and high costs. By comparison, several natural products—including huperzine A, curcumin, resveratrol, and epigallocatechin-3-gallate—demonstrate multi-target therapeutic potential through anti-inflammatory, antioxidant, and cholinergic-modulating mechanisms. This review offers a comprehensive contrast between natural products and traditional drugs as well as the safety and economic limitations of immunotherapies. Given the multifactorial nature of AD, therapeutic strategies that address multiple pathological pathways appear necessary. In this regard, plant-derived compounds, due to their broad pharmacological activity and generally favorable safety profiles, emerge as promising candidates for long-term management and may contribute meaningfully to the development of future therapeutic approaches for AD.

Drugs and Drug Candidates doi: 10.3390/ddc5010019

Authors: Antonella Quijada Benjamín Claria Paula Jiménez Paula García Álvaro Pérez María Elsa Pando

The aim of this review is to analyze current routes for the administration and absorption of vitamin B12 in older adults, with a special focus on the sublingual route using orodispersible films, and evaluate the advances, materials, and challenges associated with this method of administration. Thus, the review aims to provide an updated overview of safe and effective alternatives for preventing and treating vitamin B12 deficiency in this age group. Vitamin B12 deficiency predominantly affects older adults. After the age of 70, absorption decreases, and deficiency occurs most frequently due to age-related gastric atrophy, decreased gastric acid production, reduced intrinsic factor secretion, and inadequate dietary vitamin B12 intake. This narrative review examines traditional and current treatments for vitamin B12 administration in older adults, with a focus on sublingual administration (SL) via orodispersible films (ODFs) to enhance absorption, adherence, and accessibility. SL vitamin B12 bioavailability, advantages versus disadvantages, ODF formulations (polymers such as pregelatinized starch, HPMC, and chitosan), and pharmaceutical process challenges (solvent casting and hot-melt extrusion) were explored in the reviewed in vitro and in vivo studies. According to the collected evidence, the sublingual route appears to offer rapid absorption directly into the bloodstream, with efficacy comparable to/superior to intramuscular (IM)/oral (OP) routes of administration, representing a patient-centered innovation for older adults that overcomes painful treatments and gastrointestinal/swallowing barriers. Future longitudinal clinical trials should validate long-term efficacy, standardize materials, and scale up to viable industrial production, addressing issues related to chemical stability and polypharmacy.

Drugs and Drug Candidates doi: 10.3390/ddc5010020

Authors: Adeilso B. Santos Junior Caroline R. C. Costa João H. G. Lago Airam Roggero Igor N. Oliveira Danilo R. S. Lima Paloma P. Borges Willian H. B. C. Santos Marcos A. Oliveira Sérgio F. Sousa Marcos H. Toyama

Background/Objectives: The study investigated the anti-inflammatory potential of neolignan derivatives of dehydrodieugenol (CP1–CP5), focusing on the inhibition of secretory phospholipase A2 (sPLA2), a key enzyme in inflammation. Methods: Comprehensive quantitative docking analysis using four independent algorithms (PLP, ASP, ChemScore, GoldScore) revealed exceptional multitarget binding profiles for CP1 and CP2, with scores consistently above activity thresholds for acetylcholinesterase (AChE), cyclooxygenase-2 (COX-2), and sPLA2 from Crotalus durissus terrificus in both monomeric (Mcdt) and quaternary (Tcdt) forms. Results: Among the compounds, CP1 demonstrated the highest predicted affinity (AChE: 78.5, COX-2: 83.8, sPLA2: 82.7–83.4) and most potent experimental activity, reducing sPLA2 catalytic velocity through mixed-type inhibition involving the active site (His47, Asp48) and Ca2+ binding loop. In vivo assays in sPLA2-induced paw edema demonstrated that CP1 and CP2 achieved remarkable anti-inflammatory effects (up to 68.3% reduction), significantly exceeding their protective potential by direct enzyme inhibition, confirming the multitarget mechanism. The strong correlation between predicted docking scores and paw edema reduction (R2 = 0.89, p < 0.01) creates a firm foundation for establishing structure–activity relationship explanations. Conclusions: These findings highlight an integrated mechanism involving: (1) partial sPLA2 modulation, (2) neuroimmune regulation via AChE inhibition, and (3) prostaglandin synthesis blockade through COX-2 inhibition. This multitarget approach, combined with the natural origin of the compounds, positions dehydrodieugenol derivatives as promising candidates for developing therapies against complex inflammatory diseases, offering significant advantages over single-target strategies.

Drugs and Drug Candidates doi: 10.3390/ddc5010018

Authors: Talita Alvarenga Valdes Sabrina Mendes Botelho Keli Lima Carlos Alberto Montanari João Agostinho Machado Neto Andrei Leitão

Background: Prostate cancer is one of the most prevalent and deadly neoplasias in the male population. Despite the availability of therapies that increase the long-term survival of patients with localized tumors, metastatic prostate cancer is challenging to treat. A previous study revealed that the 2-aminopyridine derivative (named Neq0440) inhibited the PI3K-AKT-mTOR pathway and presented selective cytotoxicity toward the metastatic prostate cancer cell line PC-3. Methods: Here, we further analyzed the mechanism of action of these molecules by using cell-based colorimetric, fluorometric, epifluorescence microscopy, and Western blot assays. Results: Mitochondrial depolarization increased the AMPK level at 24 h inhibition with Neq0440, which led to the PI3K-AKT-mTOR pathway downregulation after 48 h. The phosphorylation was inhibited for AKT and the downstream quinases (S6RP and 4EBP1) from the PI3K-AKT-mTOR pathway, which can work together with the mitochondrial depolarization, lowering the pH of the medium, increasing ROS levels, and translocating the lysosomes toward the nucleus to trigger cell death. Conclusions: Therefore, Neq0440 can be used as a lead compound to obtain derivatives with a novel anticancer mechanism of action.

Drugs and Drug Candidates doi: 10.3390/ddc5010017

Authors: Rami A. Al-Horani

Cancer metabolism is a cornerstone of tumor biology, characterized by profound alterations in cellular energy production and biosynthetic pathways that drive malignancy. The seminal discovery of the “Warburg effect”, the preference of cancer cells for aerobic glycolysis even under oxygen-rich conditions, provided the first major insight into this field. Historically, this observation was attributed to defective mitochondria, but modern research has revealed a far more complex picture of metabolic reprogramming that is actively driven by oncogenes, tumor suppressor genes, and the tumor microenvironment (TME). This review advances a unifying framework for understanding cancer metabolism as a dynamic ecosystem defined by three interconnected adaptations: metabolic plasticity, oncometabolite-driven epigenetic remodeling, and immune-metabolic crosstalk. These adaptations extend beyond glycolysis to encompass glutamine metabolism, lipid synthesis, amino acid utilization, and mitochondrial dynamics, all coordinated to fuel rapid proliferation, promote survival, and enable metastasis. By examining the drivers, consequences, and therapeutic barriers within this framework, we highlight emerging strategies for precision intervention. Although understanding the mechanistic basis of these pathways has unveiled new therapeutic avenues, clinical translation has been limited by metabolic redundancy, microenvironmental buffering, and patient heterogeneity. Strategies such as metabolic inhibitors, dietary interventions, and immuno-metabolic combinations offer promising prospects for disrupting tumor growth when guided by biomarker-driven patient selection and emerging technologies, including spatial metabolomics and AI-driven network modeling.

Drugs and Drug Candidates doi: 10.3390/ddc5010016

Authors: Uche A. K. Chude-Okonkwo Mokete Motente

Background: The growing recognition of shared molecular pathways and molecular signatures between cardiovascular diseases and cancer has motivated interest in exploring antihypertensive-associated chemical space for oncological applications. Concurrently, artificial intelligence (AI)-driven molecular generation has enabled the rapid creation of virtual lead candidates for specific therapeutic indications, although their broader biological interaction profiles often remain unexplored. Methods: In this paper, we explore the computational screening of a library of AI-generated antihypertensive virtual lead compounds to evaluate their polypharmacological anticancer potential. The compounds were originally designed and prioritized for modulating β-adrenergic receptors but are here re-evaluated in a cancer-focused context using a multi-stage in silico approach. We chose five (5) known cancer target proteins and performed compound profiling for drug-likeness, pharmacokinetic suitability, and safety. Docking simulations, binding free energy estimates, molecular interaction mapping, and pharmacophore modeling were used to evaluate the molecules’ interactions with the cancer-linked protein targets. We employed the binding free energy estimates of the ligand–protein complexes to determine compounds with polypharmacological anticancer potential. In addition, molecular dynamics simulations of some of the compounds with polypharmacological anticancer potential were employed to evaluate binding stability and dynamic behavior of selected ligand–target complexes. Results: Several compounds showed good docking scores, physicochemical characteristics, and pharmacokinetic profiles. Also, the results reveal that several AI-generated antihypertensive virtual leads exhibit favorable multi-target binding profiles, with consistent docking affinities and stable interaction networks across multiple cancer-related targets. Conclusions: Our findings suggest that several of the hypothetically evaluated compounds exhibit favorable physicochemical properties, acceptable predicted pharmacokinetic and safety profiles, and consistent predicted binding affinities across multiple cancer-relevant targets.

Drugs and Drug Candidates doi: 10.3390/ddc5010015

Authors: Tanvi Premchandani Amol Tatode Jayshree Taksande Milind Umekar Mohammad Qutub Ujban Md Hussain Priyanka Singanwad

In the published manuscript [...]

Drugs and Drug Candidates doi: 10.3390/ddc5010014

Authors: Noureddine Chaachouay Lahcen Zidane

In the published manuscript [...]

Drugs and Drug Candidates doi: 10.3390/ddc5010013

Authors: Leopoldo Ardiles Carlos D. Figueroa

Chronic kidney disease (CKD) has emerged as a pervasive global health concern, for which there are no known curative treatments. Consequently, there is an imperative for the implementation of preventive and kidney-protective strategies. The renal kallikrein–kinin system (KKS) is a vasodilator, anti-inflammatory, and antifibrotic pathway located in the distal nephron, whose decline contributes to hypertension and CKD progression. In this narrative, non-systematic review, a thorough evaluation of both experimental and clinical data was undertaken to ascertain the interactions between dietary potassium, renal KKS activity, and kidney protection. A particular emphasis was placed on animal models of proteinuria, tubulointerstitial damage, and salt-sensitive hypertension, in conjunction with human studies on potassium intake and renal outcomes. A body of experimental evidence suggests a relationship between potassium-rich diets and renal kallikrein synthesis, urinary kallikrein activity, and up-regulated kinin B2 receptor expression. Collectively, these factors have been shown to result in reduced blood pressure, oxidative stress, apoptosis, inflammation, and fibrosis, and these effects are counteracted by B2 receptor blockade. In humans, higher potassium intake has been shown to enhance kallikrein excretion and lower cardiovascular and renal risk, independently of aldosterone. Conversely, low potassium intake has the potential to exacerbate CKD progression. Notwithstanding the concerns that have been raised regarding the potential necessity of increasing potassium intake in cases of advanced CKD, extant evidence would appear to indicate that potassium excretion persists until late disease stages. The activation and preservation of the renal KKS through a potassium-rich diet is a rational, cost-effective strategy for renoprotection. When combined with sodium reduction and nutritional education, this approach has the potential to halt the progression of CKD and enhance cardiovascular health on a population scale.

Drugs and Drug Candidates doi: 10.3390/ddc5010012

Authors: Henrique de Aguiar Mello Itamar Luís Gonçalves

Background/Objectives: Cephalosporins represent one of the most important classes of β-lactam antibiotics, widely used in clinical practice due to their broad-spectrum activity and favorable safety profile. As generations evolved, structural modifications were introduced to expand antimicrobial coverage and overcome β-lactamase resistance. This study aimed to analyze the drug-like properties of cephalosporins across different generations using molecular descriptors to identify structural and pharmacokinetic patterns influencing bioavailability and oral administration profiles. Methods: Thirty-eight cephalosporins representative of different generations were selected. Molecular data were obtained from PubChem, and SMILES were extracted and validated. Molecular descriptors (including MW, logP, TPSA, HBA, HBD, rotatable bonds, and global complexity indices) were calculated using the SwissADME and ChemDes platforms. Statistical analysis included ANOVA followed by post hoc tests, and principal component analysis (PCA). Results: A progressive increase in molecular weight, polarity, and TPSA was observed across generations, with fourth-generation cephalosporins showing significantly higher values compared to first-generation compounds (p < 0.0001). LogP decreased significantly in fourth-generation agents (p < 0.0001), reflecting increased polarity. PCA revealed that most compounds from generations 1–2 cluster in regions consistent with Lipinski’s and Veber’s rules, whereas fourth- and fifth generation - cephalosporins deviated substantially, prioritizing antimicrobial efficacy over oral bioavailability. Recurrent structural modifications such as oximes, tetrazoles, and aminothiazoles were identified, with increasing frequency in modern generations. Conclusions: The evolution of cephalosporins reflects a strategic shift toward enhanced antimicrobial potency and β-lactamase stability at the expense of oral bioavailability. Understanding these structural transitions provides valuable insights for rational drug design, aiming to balance antimicrobial effectiveness with favorable pharmacokinetic profiles essential for therapeutic success.

Drugs and Drug Candidates doi: 10.3390/ddc5010011

Authors: María Victoria Miró Paula Ichinose Mercedes Lloberas Carlos Lanusse Guillermo Virkel Adrián Lifschitz

Background/Objectives: The widespread development of anthelmintic resistance in gastrointestinal nematodes constitutes a major production-limiting factor in grazing ruminants. Resistance mechanisms often involve drug efflux transporters like P-glycoprotein (P-gp). This study aimed to evaluate the potential of the phytochemicals cinnamaldehyde (CNM) and thymol (TML) to modulate P-gp activity and enhance the pharmacokinetic profile and efficacy of levamisole (LVM) in lambs. Methods: An ex vivo diffusion assay using sheep ileum was conducted to assess the influence of CNM, TML, and LVM on the transport of the P-gp substrate Rhodamine 123 (Rho123). Subsequently, a clinical trial was performed in lambs naturally infected with resistant nematodes. Animals received LVM (3.75 mg/kg) subcutaneously, either alone or co-administered with CNM or TML (80 mg/kg). Plasma LVM concentrations were analyzed by HPLC, and anthelmintic efficacy was determined via the Fecal Egg Count Reduction (FECR) test. Results: Ex vivo assays demonstrated that CNM, TML and LVM significantly reduced the efflux ratio of Rho123, confirming P-gp inhibition. The pharmacokinetic parameters of LVM did not differ significantly in the co-administered groups. However, the combination of LVM + TML tended to increase the total systemic exposure of LVM. Although all experimental groups showed a significant reduction in EPG between day 0 and day 7 (FECR 50–58%), the magnitude of this reduction did not differ significantly among treatments. Conclusions: While CNM and TML effectively inhibited P-gp activity ex vivo and slightly modified LVM pharmacokinetics, these effects were insufficient to yield clinically meaningful improvements in its efficacy against nematodes under the tested conditions. Future strategies should focus on optimizing delivery systems to maximize phytochemical–drug interactions.

Drugs and Drug Candidates doi: 10.3390/ddc5010010

Authors: K. Antonio Cárdenas-Noriega Joel H. Elizondo-Luévano Abelardo Chávez-Montes Luis E. Rodríguez-Tovar Moisés A. Franco-Molina Diana G. Zárate-Triviño Raymundo A. Pérez-Hernández Adolfo Soto-Domínguez Uziel Castillo-Velázquez

Background: Phytocannabinoids such as cannabidiol (CBD) and cannabigerol (CBG) have received increasing attention in the context of inflammatory and intestinal disorders. However, direct comparisons between their individual and combined effects, as well as the influence of delivery systems, remain limited. Objectives: This study evaluated the biological effects of free and nanoencapsulated CBD and CBG, including a cannabinoid–Eudragit L100 formulation, in an in vitro TNBS-treated intestinal cell model and an in vivo murine model of TNBS-induced colitis. Methods: Cytotoxicity and treatment-associated effects of CBD, CBG, their 1:1 combination, and a nanoencapsulated formulation were assessed in TNBS-exposed Caco-2 cells. In parallel, BALB/c mice with TNBS-induced colitis were evaluated for colonic damage and inflammatory markers. Results: CBD and CBG individually showed dose-dependent effects in Caco-2 cells, while their combined administration produced a greater effect than either compound alone at higher concentrations. The nanoencapsulated formulation preserved cellular metabolic activity following TNBS exposure. In vivo, both free combined and nanoencapsulated cannabinoids were associated with reduced epithelial damage and inflammatory alterations. Conclusions: Nanoencapsulation using Eudragit L100 modulated the biological effects of CBD and CBG in experimental models of TNBS-induced intestinal injury.

Drugs and Drug Candidates doi: 10.3390/ddc5010009

Authors: Beata Franczyk Kinga Bojdo Jakub Chłądzyński Katarzyna Hossa Katarzyna Krawiranda Natalia Krupińska Natalia Kustosik Klaudia Leszto Wiktoria Lisińska Anna Wieczorek Jacek Rysz Ewelina Młynarska

Oxidative stress, caused by an imbalance between the production of reactive oxygen species and endogenous antioxidant capacity, is a key etiological factor in numerous pathologies, including neurodegenerative and cardiovascular diseases. The limited clinical efficacy of conventional antioxidants is primarily due to their insufficient accumulation within the mitochondria, the main site of intracellular ROS generation. This article reviews the design and application of Mitochondria-Targeted Antioxidants, which represent a major advance in precision medicine. The design of these compounds involves linking an antioxidant “payload” to a lipophilic cation, such as the triphenylphosphonium group. This positive charge leverages the negative electrochemical gradient across the inner mitochondrial membrane to drive the antioxidant into the organelle. This mechanism allows the drug to reach concentrations over 100 times higher than non-targeted alternatives. The discussion encompasses the structure-activity analysis of the carrier, the payload (e.g., quinone derivatives), and the linker, which determine optimal subcellular partitioning and scavenging efficiency. Preclinical data highlight the therapeutic potential of this approach, showing strong neuroprotection in models of Parkinson’s and Alzheimer’s diseases, as well as improved outcomes in cardiovascular and ocular health. By restoring redox balance specifically within the mitochondria, these targeted therapies offer a more effective way to treat chronic oxidative damage.

Drugs and Drug Candidates doi: 10.3390/ddc5010008

Authors: Thaís A. S. Oliveira Matheus H. M. Zago Larissa G. Maciel Yan R. Robles Lizandra G. Magalhães Antônio E. M. Crotti

Background/Objectives: Recent reports have demonstrated the antiparasitic activity of 1,4-dihydropyridine (1,4-DHPs). This study aimed to assess the in vitro antischistosomal activity of 24 1,4-DHPs against Schistosoma mansoni adult worms. Methods: Sixteen hexahydroquinolines (1–16) and eight Hantzsch esters (17–24) previously obtained through a multicomponent Hantzsch reaction were tested in vitro against Schistosoma mansoni adult worms. In silico studies with the most active compounds were also carried out. Results: Among the tested compounds, the Hantzsch esters 20 (diethyl 4-(4-bromophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate) and 21 (diethyl 4-(3-fluorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate) provided the lowest IC50 (15.2 and 13.1 µM, respectively) and the highest selectivity for this parasite (SI = 2.31 and >4.59, respectively). Conclusions: Docking studies revealed that compound 21 has a high affinity for the S. mansoni target (PDB ID: 6UY4). Furthermore, ADMET predictions indicated that compound 21 meets the drug-likeness criteria without violating any Lipinski, Veber, or Egan’s rules.

Drugs and Drug Candidates doi: 10.3390/ddc5010007

Authors: Govindaraj Ajith Ganesan Padmini Tamilarasi Govindaraj Sabarees Siddan Gouthaman Krishnan Manikandan Vadivel Velmurugan Veerachamy Alagarsamy Viswas Raja Solomon

In the published manuscript [...]

Drugs and Drug Candidates doi: 10.3390/ddc5010006

Authors: Paulo Juiz Matheus Porto David Moreira Davi Amor Eron Andrade

Background/Objectives: Periodontal disease is a condition marked by the destruction of tooth-supporting tissues, driven by an exaggerated immune response to an unbalanced dental biofilm. Conventional treatments struggle due to antimicrobial resistance and the biofilm’s protective extracellular matrix. This study evaluates the potential of bacteriophages as an innovative strategy for managing periodontal disease. Methods: This research employed a qualitative approach using Discursive Textual Analysis, with IRAMUTEQ version 0.8 alpha 7 (Interface de R pour les Analyses Multidimensionnelles de Textes et de Questionnaires) software. The search was conducted in the Orbit Intelligence and PubMed databases, for patents and scholarly articles, respectively. The textual data underwent Descending Hierarchical Classification, Correspondence Factor Analysis, and Similarity Analysis to identify core themes and relationships between words. Results: The analysis revealed an increase in research and patent filings concerning phage therapy for periodontal disease since 2017, emphasizing its market potential. The primary centers for intellectual property activity were identified as China and the United States. The study identified five focus areas: Genomic/Structural Characterization, Patent Formulations, Etiology, Therapeutic Efficacy, and Ecology/Phage Interactions. Lytic phages were shown to be effective against prominent pathogens such as Fusobacterium nucleatum and Enterococcus faecalis. Conversely, the lysogenic phages poses a potential risk, as they may transfer resistance and virulence factors, enhancing pathogenicity. Conclusions: Phage therapy is a promising approach to address antimicrobial resistance and biofilm challenges in periodontitis management. Key challenges include the need for the clinical validation of formulations and stable delivery systems for the subgingival area. Future strategies, such as phage genetic engineering and data-driven cocktail design, are crucial for enhancing efficacy and overcoming regulatory hurdles.

Drugs and Drug Candidates doi: 10.3390/ddc5010005

Authors: Veerabhadrappa Pallavi Sathvika Prathibha Guttal Subhas Debayan Bhattacharjee Vejetha Nagaraj Koppad Uday Samrat Sindhu Bindapla Karibasappa Kadappara Mallikarjun Sagar

In the original publication [...]

Drugs and Drug Candidates doi: 10.3390/ddc5010004

Authors: Kate Gallinero Hunter Daws Amanda Singh Sanela Bilic

The landscape of oncologic therapies has undergone large changes since the introduction of monoclonal antibody (mAb) based immunotherapies in the late 1990s and early 2000s. MAb-based therapeutics, also called biologics or large molecules, have distinct pharmacological characteristics compared to chemotherapeutics and small molecules. Development of biologics requires thorough assessment of pharmacokinetic (PK) and pharmacodynamic (PD) characteristics to ensure safety and demonstration of efficacy. This review provides an overview of the clinical pharmacology packages of biologics for the treatment of oncologic malignancies approved by the U.S. Food and Drug Administration (FDA) over the past decade (January 2015 and August 2025). The conduct of population PK (PopPK) and exposure-eesponse (E-R) analyses, as well as assessments for drug–drug interactions (DDIs), immunogenicity, and QT prolongation risk are discussed. The aim of this review is to provide insight into the clinical pharmacology assessments for approval of antibody-based therapies in oncology as well as provide a longitudinal view of clinical pharmacology packages in this space.

Drugs and Drug Candidates doi: 10.3390/ddc5010003

Authors: Sujatha M. Lokanath Manjunatha S. Katagi Girish S. Bolakatti Johnson Samuel Belakatte P. Nandeshwarappa

The journal retracts the article titled “Exploring Chalcone Derivatives as a Multifunctional Therapeutic Agent: Investigating Antioxidant Potential, Acetylcholinesterase Inhibition and Computational Insights” [...]

Drugs and Drug Candidates doi: 10.3390/ddc5010002

Authors: Vigyasa Singh Anirban Pal Mahendra P. Darokar

In the publication [...]

Drugs and Drug Candidates doi: 10.3390/ddc5010001

Authors: Elizabete Silva de Sousa Edilane Almeida da Silva Délis Galvão Guimarães Ingrid Louise Santos de Souza Arlan de Assis Gonsalves Paulo Michel Pinheiro Ferreira Rayran Walter Ramos de Sousa Marcília Pinheiro da Costa Cleônia Roberta Melo Araújo

Background/Objectives: β-Lapachone and triapine are compounds with recognized antitumor potential—the former is an ortho-naphthoquinone, and the latter a thiosemicarbazone inhibitor of ribonucleotide reductase. This study aimed to synthesize and evaluate new β-lapachone-based thiosemicarbazones (TSC1–TSC6) as potential antineoplastic agents. Methods: Lapachol was isolated from Tabebuia sp. and used to obtain ortho-naphthoquinones (2–4), which served as precursors for thiosemicarbazones (TSC1–TSC6). NMR and HRMS spectra were used to characterize the compounds. Their cytotoxic activity was evaluated in vitro against murine melanoma (B16–F10), colon carcinoma (CT26.WT), and breast cancer (4T1) cell lines, as well as normal fibroblasts (L929). Pharmacokinetic parameters were predicted in silico using ADMETLab 3.0. Results: β-Lapachone exhibited strong cytotoxicity toward tumor cells with moderate effects on normal cells, while thiosemicarbazones of β-lapachone, TSC1, and TSC3 demonstrated lower potency but greater selectivity. The β-lapachone-3-sulfonic acid showed high activity against melanoma and breast cancer cells and low toxicity toward normal cells, indicating tumor selectivity. In contrast, their thiosemicarbazones, TSC2, TSC4, and TSC6, showed weak or no antiproliferative activity. The 3-iodo-β-lapachone was cytotoxic to both tumor and normal cells, whereas its derivative TSC5 demonstrated moderate activity with reduced toxicity. β-Lapachone, β-lapachone-3-sulfonic acid, TSC1, and TSC3 exhibited favorable ADME profiles (QED ≈ 0.61–0.66), suggesting good oral bioavailability. Conclusions: The β-lapachone-3-sulfonic acid and the β-lapachone-based thiosemicarbazones TSC1 and TSC3 emerged as promising lead candidates, combining tumor selectivity, favorable pharmacokinetic properties, and structural innovation for the development of safer and more effective antineoplastic agents.

Drugs and Drug Candidates doi: 10.3390/ddc4040059

Authors: Beatriz C. T. de Oliveira Dandara de Paula Candido Acácio S. de Souza Iva S. de Jesus Fernando de C. da Silva Leonardo Bruno P. F. Barreto Samyra A. da Silveira Yrneh Y. P. Palacios Francisco das C. de Souza Maria Cristina S. Lourenço Carlos Mauricio R. Sant’Anna Vitor F. Ferreira Alcione S. de Carvalho

Background: Tuberculosis (TB) remains a critical global health concern, exacerbated by the emergence of multidrug-resistant and extensively drug-resistant strains of Mycobacterium tuberculosis. In the search for novel therapeutic agents, naphthoquinones have garnered interest due to their diverse mechanisms of action and potent antimycobacterial activity. In this study, we report the design, synthesis, and biological evaluation of a novel series of eleven naphthoquinone-based derivatives (compounds 22–32), developed through a molecular hybridization strategy targeting shikimate kinase (Mtb-SK) an essential enzyme present exclusively in M. tuberculosis. Methods: The compounds were synthesized via a straightforward and efficient synthetic route, and preliminary screening identified five molecules with significant anti-TB activity. Notably, compound 26, 4-(4-ethoxyphenyl) amino) Naphthalene-1,2-dione, exhibited a minimum inhibitory concentration (MIC) of 21.33 µM, comparable to ethambutol and substantially more potent than pyrazinamide. Results: Molecular docking studies indicated that all active compounds interact favorably within the shikimate binding pocket of Mtb-SK, following the proposed mechanism of action. Additionally, ongoing cytotoxicity assays in HepG2 cells aim to assess the selectivity of these derivatives. Conclusions: These findings support the potential of this new class of naphthoquinones as promising scaffolds for the development of anti-TB agents, contributing to the growing body of research focused on new chemotherapeutic options against tuberculosis.

Drugs and Drug Candidates doi: 10.3390/ddc4040058

Authors: Vivianne Lays Ribeiro Cavalcanti Maria Carla Santana de Arruda Thalya Natasha da Silva Santos Daniela de Araújo Viana Marques Romero Marcos Pedrosa Brandão Costa Luiza Rayanna Amorim de Lima Ana Lúcia Figueiredo Porto Raquel Pedrosa Bezerra

Background/Objectives: Colon cancer is the third most common type of cancer in the world, characterized by a high risk of metastasis, resistance to various drugs, and late diagnosis. In addition, the drugs used for treatment are associated with serious neurological damage, causing acute and chronic pain and compromising the patient’s quality of life. Meanwhile, lectins are proteins capable of exerting cytotoxic action on cells from various tumors in a selective manner, without exerting significant toxicity on healthy cells. Despite this, studies on the potential of lectins obtained from microalgae are still scarce in the literature. In this sense, the objective of this study was to evaluate the antitumor activity of lectin isolated from the microalgae Chlorella vulgaris (CvL) on colorectal cancer cells, HT-29. Methods: The purified lectin was tested for cytotoxicity using MTT colorimetric methods, in addition to clonogenicity, cell cycle, apoptosis, and necrosis tests, analyzed by flow cytometry. Results: The assays demonstrated that the lectin was able to induce cell death in the HT-29 tumor line by approximately 83.75% with an IC50 value of 21.5 µg/mL−1, reduced colony formation by more than 90%, was able to regulate the cell cycle by apoptosis, and did not present significant necrosis. These results show that microalgae lectins have the potential to be exploited in the control of neoplastic cells.

Drugs and Drug Candidates doi: 10.3390/ddc4040057

Authors: Jean Jacques Vanden Eynde

As we are closing Volume 4 of Drugs and Drug Candidates (DDC), this gives me the opportunity to share the journal’s latest developments [...]

Drugs and Drug Candidates doi: 10.3390/ddc4040056

Authors: Xareni Zinereth Herrera-Valero Sendar Daniel Nery-Flores Filiberto Gutiérrez-Gutiérrez Lizeth Guadalupe Campos-Múzquiz Sandra Cecilia Esparza-González Raúl Rodríguez-Herrera Lissethe Palomo-Ligas

Background/Objectives: Giardia lamblia is an intestinal protozoan responsible for giardiasis, a globally prevalent parasitic disease. Current therapeutic options, including nitroimidazoles and benzimidazoles, have increasing treatment failures due to resistance, adverse reactions, and patient non-compliance. Drug repositioning offers a cost-effective strategy for identifying new antigiardial agents. This study aimed to evaluate the in vitro antiparasitic effects and possible mechanisms of action of the tricyclic antidepressant imipramine against G. lamblia trophozoites. Methods: Trophozoites were exposed to increasing concentrations of imipramine (25–125 µM). Growth inhibition and adhesion capacity were quantified using cell counts. Apoptosis- or necrosis-like death was evaluated through Annexin V/PI staining. The expression and distribution of α-tubulin and lipid rafts were analyzed by immunofluorescence microscopy. Finally, the effect of the drug on encystment efficiency was assessed in vitro. Results: Imipramine inhibited G. lamblia trophozoite growth in a concentration-dependent manner, with an IC50 of 42.31 µM at 48 h. The drug significantly reduced adhesion capacity (>90% at 125 µM) and induced apoptosis-like cell death, as evidenced by Annexin V positivity. Immunofluorescence revealed disruption of α-tubulin distribution and lipid raft organization, accompanied by morphological rounding. Moreover, encystment efficiency decreased in a concentration-dependent mode, suggesting interference in the differentiation process. Conclusions: This investigation describes, for the first time, the antigiardial potential of imipramine, which alters cytoskeletal organization, membrane microdomains, and differentiation pathways, ultimately leading to apoptosis-like cell death. These findings position this compound as a promising lead structure and support further exploration of tricyclic antidepressants as scaffolds for the development and optimization of new antiparasitic agents, as well as future studies on their molecular targets and in vivo efficacy.

Drugs and Drug Candidates doi: 10.3390/ddc4040055

Authors: Romina Manarin Gianfranco Frattini Victoria L. Alonso Victoria Boselli Giselle R. Bedogni Elvio Rodríguez Araya Diego M. Moreno Esteban Serra

Background: In recent years, compounds known as Proteolysis Targeted Chimeras (PROTACs) have revitalized the field of bioactive molecule design. These compounds promote proteolysis of therapeutic targets by recruiting them to ubiquitin ligases. One of the most commonly used classes of compounds in the synthesis of PROTACs are immunomodulatory imides (IMiDs), such as thalidomide (TLD), which interact with the E3 ligase CRL4CRBN via the CULT domain of the cereblon protein (CRBN). This domain has been identified in proteins across various phylogenetic groups, including trypanosomatids, leading to the hypothesis that IMiD-derived PROTACs should be active in these organisms. Methods: The trypanocidal activity of the PROTAC dBET1 and its separated components (JQ1 and TLD) were assayed using a T. cruzi strain expressing β-glalactosidase. Potential CRL4-E3L complexes from humans and trypanosomatids were assembled in silico with MultimerMapper. The IMiD-binding site of HsCRBN and its trypanosomatid homologs were analyzed using molecular dynamics and docking simulations. Results: We demonstrate that the compound dBET1 does not function as a PROTAC in Trypanosoma cruzi. In silico structural analysis of CRL4-E3L complex orthologs revealed that the trypanosomal CULT-containing protein is not part of such a complex. Molecular dynamics simulations showed that the pocket of this CULT domain is smaller than that of mammalian CRBN and cannot accommodate IMiDs within. Conclusions: We underscore the importance of functional and structural validation in drug discovery, particularly when extrapolating mechanisms between evolutionarily distant species. While PROTACs hold promise in human therapeutics, our work advocates for re-evaluating the rationale behind thalidomide-based PROTACs in trypanosomatid research.

Drugs and Drug Candidates doi: 10.3390/ddc4040054

Authors: Palloma Lima de Oliveira José Rafael da Silva Araújo Camila Marinho da Silva Kyria Cilene de Andrade Bortoleti Silvany de Sousa Araújo Márcia Vanusa da Silva Dráulio Costa da Silva Marcos dos Santos Lima Ana Paula de Oliveira Ana Christina Brasileiro-Vidal

Background/Objectives: Bauhinia cheilantha Bong. Steud. (Leguminosae; “pata-de-vaca”) is traditionally used in folk medicine for its antidiabetic, anti-inflammatory, and sedative properties. This study aimed to evaluate aqueous leaf extracts of B. cheilantha, non-delipidated and delipidated, regarding their phytochemical composition, phenolic profile, antioxidant potential, and cytotoxic, genotoxic, and antigenotoxic effects. Methods: Phytochemical screening was performed by TLC, and phenolic compounds were determined by HPLC. Antioxidant activity was assessed using DPPH, ABTS, and phosphomolybdenum assays. Cytotoxicity, genotoxicity, and antigenotoxicity were evaluated in L929 murine fibroblast cells using MTT and cytokinesis-block micronucleus (CBMN) assays. Results: Both extracts contained anthocyanins, phenolics, lignans, saponins, and hydrolyzable tannins. The delipidated extract showed higher total phenolic content (17.54 mg/kg) than the non-delipidated (13.76 mg/kg). Major constituents included kaempferol 3-glucoside, quercetin, hesperidin, naringenin, and t-cinnamic acid. Antioxidant assays revealed EC50 values of 25.84, 13.60, and 66.09 µg/mL for the non-delipidated extract, and 26.19, 16.34, and 52.78 µg/mL for the delipidated extract in the DPPH, ABTS, and phosphomolybdenum assays, respectively. No cytotoxicity was observed, except at 1600 µg/mL for the non-delipidated extract and 800–1600 µg/mL for the delipidated extract. Genotoxicity occurred only at 400 µg/mL. Antigenotoxic evaluation showed that the non-delipidated extract (100 µg/mL) reduced methyl methanesulfonate-induced chromosomal damage in simultaneous and post-treatment conditions, while the delipidated extract was only effective for post-treatment. Conclusions: Aqueous extracts of B. cheilantha exhibit antioxidant and antigenotoxic properties. At active concentrations, they were non-cytotoxic and non-genotoxic. The non-delipidated extract, in particular, showed the strongest genome-protective potential, supporting its traditional use and highlighting its relevance in the development of natural therapeutic agents.

Drugs and Drug Candidates doi: 10.3390/ddc4040053

Authors: Mihira Gutti Melanie Tsui Stella Yang Selina Xi Jennifer Luo Arshia Desarkar Yining Xie Mirabelle Feng Udbhav Avadhani Shloka Raghavan Elena Brierley-Green Erika Yu Edward Njoo

Background/Objectives: Vincamine is an indole alkaloid initially isolated from plants of the Vinca genus and has previously been demonstrated to have antioxidant, hypoglycemic, and hypolipidemic activities. Vinpocetine, a synthetic derivative of vincamine with an enhanced pharmacological profile, has demonstrated promising antiproliferative properties. While previously reported vinpocetine derivatives have undergone extensive investigation for their pharmacological properties, the role of the E-ring ethyl ester in the antiproliferative properties of compounds with this scaffold has not yet been fully described. Methods: Here, the antiproliferative activity of two vinpocetine analogs with modifications at the E-ring was evaluated through cell viability and LDH assays, and their mechanism of action was investigated through cell cycle analysis, apoptosis detection, and reporter assays for Wnt-1, NF-κB, and STAT3 signaling. Results: Cell viability assays revealed that reduction of the ethyl ester to an alcohol exhibited strong dose-dependent antiproliferative activity across five mammalian cell lines, but did not induce significant markers of apoptosis or necrotic death as determined by FITC/Annexin V and cell cycle flow cytometry, respectively. Through label-free cell imaging, we found the antiproliferative activity of vinpocetine alcohol to be correlated with a decrease in membrane integrity in treated cells. We further observe that both analogs exhibit dose-dependent modulation of TCF/LEF, NF-kB, and STAT3 reporter cells, which appears to be coupled with trends in antiproliferative activity. Conclusions: Altogether, this work demonstrates the potential for E-ring modifications of vinpocetine as antiproliferative agents.

Drugs and Drug Candidates doi: 10.3390/ddc4040052

Authors: Giovanna Capaldi Fortunato Gabriel Davi Marena Débora Eduarda Soares Silva Tamara Renata Machado Ribeiro Cristiano Gallina Moreira Flávia Aparecida Resende Nogueira Leonardo Delello Di Filippo Marlus Chorilli Adelino Vieira de Godoy Netto Taís Maria Bauab

Introduction: The increasing prevalence of fungal infections, particularly those caused by Candida albicans, presents a significant clinical challenge due to the emergence of drug-resistant strains. Silver (I) coordination complexes show promise as antifungal agents; however, their poor water solubility limits clinical application. Methods: In this study, we developed and characterized a lipid nanoemulsion (Ag-LN) to enhance the delivery and activity of a silver (I) complex. Results: The formulation exhibited nanoscale size, spherical morphology, and stability for up to 60 days. Ag-LN showed potent antifungal effects, preventing biofilm formation and eradicating mature biofilms. Importantly, nanoencapsulation preserved antifungal activity while reducing mutagenic potential and acute toxicity compared with the free compound. Conclusions: These findings support Ag-LN as a promising antifungal platform for future preclinical studies.

Drugs and Drug Candidates doi: 10.3390/ddc4040051

Authors: Oyinlola Oluwunmi Olaokun

Background: Type 2 diabetes mellitus (T2DM) is a complex metabolic disease requiring multi-targeted therapeutic strategies. Gunnera perpensa and Erythrina zeyheri are traditionally used in diabetes management, but their mechanisms remain poorly understood. Methods: This study used in vitro, metabolomics, and network pharmacology approaches to elucidate their antidiabetic potential. Leaf extracts were screened for glucose utilization in C2C12 cells, and cytotoxicity in Vero cells. Metabolites profiled via GC×GC-TOF-MS and those retrieved from Phytochemical Interaction Database were evaluated for drug-likeness and target prediction using SwissADME and SwissTargetPrediction. Diabetes-related targets were obtained from databases, and overlapping targets were used to construct interaction networks using Cytoscape and STRING. Functional enrichment analyses were conducted via DAVID for GO and KEGG pathways. Results: G. perpensa acetone and methanol extracts enhanced superior glucose utilization (IC50 = 78.5 and 94.8 µg/mL, respectively), with low cytotoxicity (LC50 > 600 µg/mL). Key compounds including arabinose, identified from both plants, showed multi-target binding potential against STAT3, PIK3RI and JAK2. Enrichment analyses revealed pathways related to insulin signaling, inflammation, and glucose metabolism. Conclusions: This study supports the therapeutic relevance of phytochemical synergy in the traditional use of both plants and demonstrated systems-level approaches for elucidating complex drug–target interactions in T2DM.

Drugs and Drug Candidates doi: 10.3390/ddc4040050

Authors: Madhumita Aggunna Chiranjeevi V. M. Ganteti Keerthi R. Bhukya Meghana Mathangi Joyjethin Neelam Aswitha Gurrala Bavana Grandhi Noahjeevan Vejendla Sriharshini Mathangi Swarnalatha Gudapati Ravikiran S. Yedidi

Background/Objectives: Molnupiravir (MOV) and nirmatrelvir (NMV) are antiviral drugs that were FDA-approved under the emergency use authorization (EUA) for coronavirus disease-2019 (COVID-19) treatment. MOV and NMV target the viral RNA-dependent RNA polymerase and main protease, respectively. Paxlovid is a combination of NMV and ritonavir (RTV), an inhibitor of the human cytochrome P450-3A4 (hCYP3A4). In this study, the structural consequences in the hCYP3A4 caused by MOV-induced mutations (MIM) were evaluated using in silico tools. Methods: MOV-induced mutations (MIM) were inserted into all the possible hotspots in the active site region of the hCYP3A4 gene, and mutant protein models were built. Structural changes in the heme-porphyrin ring of hCYP3A4 were analyzed in the presence and absence of substrates/inhibitors, including RTV. Molecular dynamics (MD) simulations were performed to analyze the effect of MIM-induced structural changes in hCYP3A4 on drug binding. Results: MD simulations confirm that MIMs, R375G and R440G in hCYP3A4 severely affect the heme-porphyrin ring stability by causing a tilt that in turn affects RTV binding, suggesting a possible inefficiency in the function of hCYP3A4. Similar results were seen for amlodipine, atorvastatin, sildenafil and warfarin, which are substrates of hCYP3A4. Conclusions: The current in silico studies indicate that hCYP3A4 containing MIMs can create complications in the treatment of COVID-19 patients, particularly with co-morbidities due to its functional inefficiency. Hence, clinicians must be vigilant when using MOV in combination with other drugs. Further in vitro studies focused on hCYP3A4 containing MIMs are currently in progress to support our current in silico findings.

Drugs and Drug Candidates doi: 10.3390/ddc4040049

Authors: Maria Chalkioti Thomas Papikinos Marios G. Krokidis Panagiotis Vlamos Themis P. Exarchos

Background/Objectives: Despite continuous pharmacological advances, the treatment of schizophrenia remains challenging, and suboptimal outcomes are still too frequent. There are currently limited new approved drugs without resistance. Methods: For this reason, drug repurposing presents a promising solution for identifying existing drugs with therapeutic effects for schizophrenia. In this study, we provide a workflow of signature-based drug repurposing methodology. We initially utilized a dataset from Gene Expression Omnibus which consists of RNA sequence data from blood-derived leukocyte samples from individuals with schizophrenia and control subjects, and conducted an analysis. Results: This analysis identified 1205 statistically significant differentially expressed genes, of which 150 upregulated and 150 downregulated genes were used in the CMap and L1000CDS2 tools. Then, each database generated a list of potential compounds that could reverse the disease’s signature and potentially have therapeutic effects for schizophrenia. Subsequently, the compounds associated with the disease, as identified in the research, were chemically clustered, and then their modes of action were predicted. In the last stage, we conducted a literature review to evaluate the relationship of these modes of action with the disease. Conclusions: This systematic analysis provided a list of potential drugs for schizophrenia treatment so that their efficacy can be evaluated in the wet-lab experiments, which is the next stage of drug repurposing.

Drugs and Drug Candidates doi: 10.3390/ddc4040048

Authors: Georg Voelcker

This paper does not describe the results of a systematic search for the mechanism of action of cyclophosphamide and the consequences and possible indications arising from this mechanism. Rather, it describes a puzzle in which our own results, with some of them being very old, were re-evaluated with the latest biochemical knowledge and supplemented by results from the scientific literature. The mechanism of action of cyclophosphamide, which has been indispensable in clinical practice for 60 years, was unknown until recently simply because biochemical knowledge was lacking and because results from in vitro experiments were uncritically extrapolated to in vivo conditions. In vitro, the DNA alkylating metabolite phosphoramide mustard (PAM) is formed from the CP metabolite aldophosphamide (ALD) by phosphate and bicarbonate ion-catalyzed β-elimination of acrolein; in vivo, however, ALD is cleaved by phosphoesterases or DNA polymerase δ and ε, which are associated with 3′-5′ exonucleases, into the complementary metabolites PAM and 3-hydroxypropanal (HPA). The following describes the mechanism of action of CP, namely the complementary interaction of alkylating PAM and apoptosis-enhancing HPA, and it is shown that by optimizing the complementary effects of PAM and HPA, the antitumor efficacy in the P388 mouse tumor model can be increased by more than ten thousand-fold. Further experiments show that by optimizing the interaction of DNA alkylation and enhancing the resulting apoptosis by HPA, the formation of resistant metastases can be prevented and low-toxicity chemotherapy can be achieved.

Drugs and Drug Candidates doi: 10.3390/ddc4040047

Authors: Sean P. Bradley Jazmin M. Galván Achi Laura Cooper Malaika D. Argade Han Cheng Ryan Bott Christian A. Zielinski Arsen M. Gaisin Luke T. Jesikiewicz José A. Villegas Hyun Lee Kiira Ratia Norton P. Peet Lijun Rong Irina N. Gaisina

Background/Objectives: We have established a robust, cell-based high-throughput screening platform capable of identifying SARS-CoV-2 entry inhibitors within a BSL-2 facility. Methods: Using a curated compound library, we conducted a screening campaign that led to the discovery of potent viral entry inhibitors active in both pseudoviral and infectious SARS-CoV-2 inhibition assays. Results: Among those, Hit-1 exhibited submicromolar antiviral activity across all tested SARS-CoV-2 strains, including the highly transmissible Omicron subvariants. Biophysical binding assays confirmed that Hit-1 and related compounds directly engage the prefusion-stabilized SARS-CoV-2 spike proteins of both authentic WA1/2020 and Omicron viral strains. To elucidate potential binding orientations and interactions of the hit compounds with the SARS-CoV-2 spike protein, molecular docking studies were performed targeting two putative binding sites. Conclusions: Preliminary structure–activity relationship studies identified a promising subset of drug-like 7,8-dihydropyrido[4,3-d]pyrimidine-based inhibitors with potential for further development as novel therapeutic agents aimed at blocking viral entry and thereby preventing or mitigating SARS-CoV-2 infection. Among these, compound 13 stands out due to its superior in vitro potency and favorable pharmacokinetic properties, positioning it as a strong candidate for in vivo efficacy evaluation.

Drugs and Drug Candidates doi: 10.3390/ddc4040046

Authors: Seyede Nafise Tabatabaei Zahra Keykhaee Saghi Nooraei Mohammad Amin Ayati Mohammad Behzadmand Saba Azimi Fatemeh Eskati Gholamreza Ahmadian

In the published manuscript [...]

Drugs and Drug Candidates doi: 10.3390/ddc4040045

Authors: Pedro Artur Ferreira Marinho Wêndeo Kennedy Costa Maria Tereza dos Santos Correia Wliana Alves Viturino da Silva Magda Rhayanny Assunção Ferreira Luiz Alberto Lira Soares José Jailson Lima Bezerra Alisson Macário de Oliveira

Background/Objectives: This study investigated the flavonoid enrichment and antimicrobial activity of the ethyl acetate fraction (EAF) obtained from Croton blanchetianus (Euphorbiaceae) leaves against Staphylococcus aureus, including the methicillin-resistant strains (MRSA) that were isolated, as well as its possible mechanism of action. Methods: Croton blanchetianus leaves were extracted with ethanol:water (50%), then the extract was spray-dried and partitioned (8×) with ethyl acetate. Phytochemical analysis was performed using thin layer chromatography (TLC), while antibacterial activity was conducted using minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) methods. Results: Chemical profiling (TLC) confirmed multiple flavonoid bands and the presence of hyperoside; the total flavonoid content in the EAF reached 25.3% (≈2.28× the spray-dried extract and 6.65× the aqueous fraction). The MIC and MBC assays against S. aureus ATCC 29213 and six clinical isolates showed an MIC of 4–32 μg/mL and an MBC of 16–64 μg/mL for EAF. The combination of EAF with chloramphenicol showed a complete synergistic effect for S. aureus ATCC 29213 and S. aureus UFPEDA 705, a partial effect for S. aureus UFPEDA-659 and S. aureus UFPEDA-671, antagonistic effect for S. aureus UFPEDA 731 and S. aureus UFPEDA 802, and no effect for S. aureus UFPEDA-691. Growth curves indicated time- and concentration-dependent inhibition. Membrane integrity assays revealed K+ efflux and release of DNA/RNA and proteins, suggesting bacterial membrane destabilization as a likely mechanism. Conclusions: The flavonoid-rich fraction of C. blanchetianus exhibits potent anti-S. aureus activity, including MRSA. Furthermore, it was observed that EAF has a synergistic effect with chloramphenicol and acts through membrane damage, making it a candidate for a phytoderived adjuvant in antimicrobial therapies.

Drugs and Drug Candidates doi: 10.3390/ddc4040044

Authors: Deepak Kumar Semwal Ankit Kumar Ruchi Badoni Semwal Nand Kishor Dadhich Ashutosh Chauhan Vineet Kumar

Background/Objectives: Natural products, especially plant metabolites, play a crucial role in drug development and are widely used in medicine, cosmetics, and nutrition. The present review aims to provide a comprehensive overview of the pharmacological profile of Glycyrrhizin (GL), with a specific focus on its molecular targets. Methods: Scientific literature was thoroughly retrieved from reputable databases, including Scopus, Web of Science, and PubMed, up to 30 July 2025. The keywords “glycyrrhizin” and “glycyrrhizic acid” were used to identify relevant references, with a focus on pharmacological applications. Studies on synthetic analogs, non-English publications, non-pharmacological applications, and GL containing crude extracts were largely excluded. Results: Glycyrrhizin, the major bioactive constituent of Glycyrrhiza glabra, exhibits diverse pharmacological activities, including anti-inflammatory, antiviral, hepatoprotective, antitumor, neuroprotective, and immunomodulatory effects. These actions are primarily mediated through the inhibition of high-mobility group box 1 (HMGB1) and the modulation of key signaling pathways, including nuclear factor kappa B (NF-κB), mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase/protein kinase B (PI3K/Akt), and various cytokine networks. As a result of its therapeutic potential, GL-based formulations, including Stronger Neo-Minophagen C, and GL-rich extracts of G. glabra are commercially available as pharmaceutical preparations and food additives. Conclusions: Despite its therapeutic potential, the clinical application of GL is limited by poor oral bioavailability, metabolic variability, and adverse effects such as pseudoaldosteronism. Hence, careful consideration of pharmacokinetics and safety is essential for translating its therapeutic potential into clinical practice.

Drugs and Drug Candidates doi: 10.3390/ddc4030043

Authors: Noureddine Chaachouay

In the published publication [...]

Drugs and Drug Candidates doi: 10.3390/ddc4030042

Authors: Leyla Salimova Ali Sahin Ozge Ardicli Fatima Hacer Kurtoglu Babayev Zeynep Betul Sari Muhammed Emin Sari Muhammet Guzel Kurtoglu Sena Ardicli Huseyn Babayev

Background/Objectives: Human Herpes Simplex Virus 1 (HSV-1) is a common pathogen that establishes lifelong latent infections. The emergence of drug resistance necessitates novel therapeutic strategies. This study introduces a novel antiviral approach: a bivalent degrader designed to induce the degradation of an essential protein. Methods: A structural model of ICP0, generated via the Chai-1 AI platform, was analyzed with fpocket, P2Rank, and KVFinder to identify a superior allosteric target site. An iterative de novo design workflow with CReM-dock then yielded a lead scaffold based on its predicted affinity and drug-like properties. This selected “warhead” was used to rationally design the final bivalent degrader, ICP0-deg-01, for the ICP0 dimer model. Results: The generative process yielded a lead chemical scaffold that was selected based on its predicted binding affinity and favorable drug-like properties. This scaffold was used to rationally design a single candidate bivalent degrader, ICP0-deg-01. Our structural model predicts that ICP0-deg-01 can successfully bridge two ICP0 protomers, forming an energetically favorable ternary complex. Conclusions: This work provides a computational proof-of-concept for a novel class of anti-herpetic agents and identifies a lead candidate for future molecular dynamics simulations and experimental validation.

Drugs and Drug Candidates doi: 10.3390/ddc4030041

Authors: Fernanda F. Souza Juliana F. Vilachã Othon S. Campos Heberth de Paula

Background/Objectives: Malaria is a prominent vector-borne disease, with a high mortality rate, particularly in children under five years old. Despite the use of various insecticides for its control, the emergence of resistant mosquitoes poses a significant public health threat. Acetylcholinesterase (AChE) is a crucial enzyme in nerve transmission and a primary target for insecticide development due to its role in preventing repeated nerve impulses. Recent studies have identified difluoromethyl ketone (DFK) as a potent inhibitor of both sensitive and resistant Anopheles gambiae acetylcholinesterase (AgAChE). This study aimed to identify novel AgAChE inhibitors that could be explored for malaria prevention. Methods: We performed a virtual screening on the PubChem database using a pharmacophore model from difluoromethyl ketone-inhibited AgAChE’s crystal structure. The most promising compound was then subjected to molecular docking and dynamics studies with AgAChE to confirm initial findings. ADMET and agrochemical likeness (ag-like) properties were also analyzed to assess its potential as an agrochemical agent. Results: PubChem18463786 was identified as the most suitable compound from the virtual screening. Molecular docking and molecular dynamics studies confirmed its strong interaction with AgAChE. The ADMET and ag-like analyses indicated that PubChem18463786 possesses physicochemical properties suggesting a high probability of non-absorption in humans and meets the criteria for agrochemical similarity. Conclusions: Our findings suggest that PubChem18463786 is a potential AgAChE inhibitor candidate. After validation through in vitro and in vivo experiments, it could be exploited for malaria prevention and serve as a lead compound for the synthesis of new, more effective, and selective agrochemical agents.

Drugs and Drug Candidates doi: 10.3390/ddc4030040

Authors: Atziri Alejandra Jiménez-Fernández Joceline Alejandra Grajeda-Perez Sofía de la Paz García-Alcázar Mariana Gabriela Luis-Díaz Francisco Javier Granada-Chavez Emiliano Peña-Durán Jesus Jonathan García-Galindo Daniel Osmar Suárez-Rico

Substance use during pregnancy is an increasingly important yet under-recognized threat to maternal and child health. This narrative review synthesizes the current evidence available on the epidemiology, pathophysiology, clinical management, and policy landscape of prenatal exposure to alcohol, tobacco, opioids, benzodiazepines, cocaine, cannabis, methamphetamines, and other synthetic drugs. All major psychoactive substances readily cross the placenta and can remain detectable in breast milk, leading to a shared cascade of obstetric complications (hypertensive disorders, placental abruption, pre-term labor), fetal consequences (growth restriction, structural malformations), and neonatal morbidities such as neonatal abstinence syndrome and sudden infant death. Mechanistically, trans-placental diffusion, oxidative stress, inflammatory signaling, and placental vascular dysfunction converge to disrupt critical neuro- and cardiovascular developmental windows. Early identification hinges on the combined use of validated screening questionnaires (4 P’s Plus, CRAFFT, T-ACE, AUDIT-C, TWEAK) and matrix-specific biomarkers (PEth, EtG, FAEE, CDT), while effective treatment requires integrated obstetric, addiction, and mental health services. Medication for opioid use disorders, particularly buprenorphine, alone or with naloxone, confers superior neonatal outcomes compared to methadone and underscores the value of harm-reducing non-punitive care models. Public-health strategies, such as Mexico’s “first 1 000 days” framework, wrap-around clinics, and home-visiting programs, demonstrate the potential of multisectoral interventions, but are hampered by structural inequities and punitive legislation that deter care-seeking. Research gaps persist in polysubstance exposure, culturally tailored therapies, and long-term neurodevelopmental trajectories. Multigenerational, omics-enabled cohorts, and digital longitudinal-care platforms represent promising avenues for closing these gaps and informing truly preventive perinatal health policies.

Drugs and Drug Candidates doi: 10.3390/ddc4030039

Authors: Sandra Albenque-Rubio Jean Guillon Patrice Agnamey Céline Damiani Solène Savrimoutou Luisa Ronga Marie Hanot Tshering Zangmo Noël Pinaud Stéphane Moreau Jean-Louis Mergny Mathieu Marchivie Serge Moukha Fabienne Estela Pascale Dozolme Anita Cohen Pascal Sonnet

Background: Based on our previously reported series of novel 1,3,5-tris[(4-(substituted-aminomethyl)phenyl)methyl]benzene and 1,3,5-tris[(4-(substituted-aminomethyl)phenoxy)methyl]benzene derivatives, we have now designed, synthesized, and tested a new series of novel restricted and simplified structural analogues of these compounds against Plasmodium falciparum in vitro; i.e., the 1,3-bis[(4-(substituted-aminomethyl)phenyl)methyl]benzene and 1,3-bis[(4-(substituted-aminomethyl)phenoxy)methyl]benzene compounds. Methods & Results: The pharmacological results revealed significant antimalarial activity, with IC50 values in the submicromolar to micromolar range. Additionally, the in vitro cytotoxicity of these new nitrogen-containing polyphenyl- or -phenoxymethylbenzene compounds was evaluated on human HepG2 cells. The compound 1f, the 1,3-bis[(4-(3-(morpholin-1-yl)propyl)aminomethyl)phenoxy)methyl]benzene derivative, emerged as one of the most potent and promising antimalarial candidates, demonstrating a cytotoxicity/antiprotozoal activity ratio of 594 against the chloroquine-sensitive Plasmodium falciparum 3D7 strain. Additionally, the 1,3-bis[((substituted aminomethyl)phenyl)methyl]benzene compound 1j and the 1,3-bis[((substituted aminomethyl)phenoxy)methyl]benzenes 2p and 2q also showed strong antimalarial potential, with selectivity indexes (SI) of over 303, 280, and 217, respectively, against the 3D7 strain, which has mefloquine-reduced sensitivity. Furthermore, the 1,3-bis[(4-(pyridin-2-ylethylaminomethyl)phenyl)methyl]benzene 2k was identified as the most noteworthy antimalarial compound, exhibiting a selectivity index (SI) that was superior to 178 against the chloroquine-resistant Plasmodium falciparum W2 strain. It has previously been suggested that the telomeres of P. falciparum may serve as potential targets for these polyaromatic compounds; thus, we assessed the ability of our novel derivatives to stabilize parasitic telomeric G-quadruplexes using a FRET melting assay. Conclusions: However, regarding the stabilization of the protozoan G-quadruplex, it was noted that the few substituted derivatives, which showed interesting stabilization profiles, were not necessarily the most effective antimalarial compounds against both Plasmodium strains. Moreover, these new compounds did not show promising stabilizing effects on the different G4 sequences. Therefore, no correlation arises between their antimalarial activity and the selectivity of their binding to G-quadruplexes.

Drugs and Drug Candidates doi: 10.3390/ddc4030038

Authors: Nalia Mekarnia Sandrine Cojean Philippe M. Loiseau

Background: Drug development for leishmaniases treatment follows a very selective process in order to propose drug candidates that possess all the qualities that meet the strict specifications of the pharmaceutical industry. Drug resistance is a limiting factor that can impact the lifespan of a marketed drug. It is now essential that the risk of drug resistance be evaluated at the early stage of in vitro studies to discard a lead compound that could quickly generate drug resistance once available on the market. Objectives: This article aims to estimate the risk of drug resistance emergence for a promising drug candidate at the in vitro early stage of drug development. Methods: A sequential method is proposed to study some of the phenotypic characteristics and parameters of resistant parasites such as time to achieve maximal resistance during stepwise drug pressure, resistance amplitude, stability, fitness, and infectivity both in vitro and in vivo. Results: Some examples with drugs in clinical use and former drug candidates are given. Conclusions: This method providing an evaluation of the risk of drug resistance from an in vitro model of Leishmania donovani be extrapolated to other Leishmania species.

Drugs and Drug Candidates doi: 10.3390/ddc4030037

Authors: Jéssica Branquinho Raquel Leão Neves Michael Bader João Bosco Pesquero

The kallikrein–kinin system and its B1 and B2 receptors are key regulators in metabolic disorders such as obesity, diabetes, and insulin resistance. Obesity, a chronic and multifactorial condition often associated with comorbidities like type 2 diabetes and dyslipidemia, remains poorly understood at the metabolic level. The kinin B2 receptor (B2R) is involved in blood pressure regulation and glucose metabolism, promoting glucose uptake in skeletal muscle via bradykinin. Studies in B2R-KO mice demonstrate that the absence of this receptor predisposes animals to glucose intolerance under a high-fat diet and impairs adaptive thermogenesis, indicating a protective role for B2R in metabolic homeostasis and insulin sensitivity. In contrast, the kinin B1 receptor (B1R) is inducible under pathological conditions and is activated by kinin metabolites. Mouse models lacking B1R exhibit improved metabolic profiles, including protection against high-fat diet-induced obesity and insulin resistance, enhanced energy expenditure, and increased leptin sensitivity. B1R inactivation in adipocytes enhances insulin responsiveness and glucose tolerance, supporting its role in the development of insulin resistance. Moreover, B1R deficiency improves energy metabolism and thermogenic responses to adrenergic and cold stimuli, promoting the activation of brown adipose tissue and the browning of white adipose tissue. Collectively, these findings suggest that B1R and B2R represent promising therapeutic targets for the treatment of metabolic disorders.

Drugs and Drug Candidates doi: 10.3390/ddc4030036

Authors: Ashish Dhiman Kalpna Garkhal

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder primarily targeting joints, leading to pain, swelling, and stiffness. RA results from the body’s own immune system attacking its own tissues. Currently, there are various treatments available for RA including disease-modifying antirheumatic drugs (DMARDs) and NSAIDs. Leflunomide (LEF) is a USFDA-approved synthetic DMARD which is being widely prescribed for the management of RA; however, it faces several challenges such as prolonged drug elimination, hepatotoxicity, and others. LEF exerts its therapeutic effects by inhibiting dihydroorotate dehydrogenase (DHODH), thereby suppressing pyrimidine synthesis and modulating immune responses. Emerging nanotechnology-based therapies help in encountering the current challenges faced in LEF delivery to RA patients. This review enlists the LEF’s pharmacokinetics, mechanism of action, and clinical efficacy in RA management. A comparative analysis with methotrexate, biologics, and other targeted therapies, highlighting its role in monotherapy and combination regimens and the safety concerns, including hepatotoxicity, gastrointestinal effects, and teratogenicity, is discussed alongside recommended monitoring strategies. Additionally, emerging trends in novel formulations and drug delivery approaches are explored to enhance efficacy and minimize adverse effects. Overall, LEF remains a perfect remedy for RA patients, specifically individuals contraindicated with drugs like methotrexate. The therapeutic applicability of LEF could be enhanced by developing more customized treatments and advanced drug delivery approaches.

Drugs and Drug Candidates doi: 10.3390/ddc4030035

Authors: Takudzwa Ndhlovu Uche A. K. Chude-Okonkwo

Background: Hypertension is a serious global health issue affecting over one billion adults and leading to severe complications if left unmanaged. Despite medical advancements, only a fraction of patients effectively have their hypertension under control. Among the factors that hinder adherence to hypertensive drugs are the debilitating side effects of the drugs. The lack of adherence results in poorer patient outcomes as patients opt to live with their condition, instead of having to deal with the side effects. Hence, there is a need to discover new hypertension drug molecules with better side effects to increase patient treatment options. To this end, computational methods such as artificial intelligence (AI) have become an exciting option for modern drug discovery. AI-based computational drug discovery methods generate numerous new lead antihypertensive drug molecules. However, predicting their potential side effects remains a significant challenge because of the complexity of biological interactions and limited data on these molecules. Methods: This paper presents a machine learning approach to predict the potential side effects of computationally synthesised antihypertensive drug molecules based on their molecular properties, particularly functional groups. We curated a dataset combining information from the SIDER 4.1 and ChEMBL databases, enriched with molecular descriptors (logP, PSA, HBD, HBA) using RDKit. Results: Gradient Boosting gave the most stable generalisation, with a weighted F1 of 0.80, and AUC-ROC of 0.62 on the independent test set. SHAP analysis over the cross-validation folds showed polar surface area and logP contributing the largest global impact, followed by hydrogen bond counts. Conclusions: Functional group patterns, augmented with key ADMET descriptors, offer a first-pass screen for identifying side-effect risks in AI-designed antihypertensive leads.

Drugs and Drug Candidates doi: 10.3390/ddc4030034

Authors: Katsumi Iga

Background/Objective: Cerivastatin (Cer), a cholesterol-lowering statin, was withdrawn from the market due to fatal cases of rhabdomyolysis, particularly when co-administered with gemfibrozil (Gem), a strong CYP2C8 inhibitor. However, the pharmacokinetic (PK) mechanisms underlying these adverse events remain unclear. This study investigates the impact of drug–drug interactions (DDIs) involving Gem and itraconazole (Itr), a potent CYP3A4 inhibitor, on plasma concentrations of Cer and its major metabolites—M23, M1, and cerivastatin lactone (Cer-L)—with a focus on the risk of excessive Cer-L accumulation. Methods: We applied a newly developed Metabolite-Linked Model that simultaneously characterizes parent drug and metabolite kinetics by estimating metabolite formation fractions (fM) and elimination rate constants (KeM). The model was calibrated using observed DDI data from Cer + Gem and Cer + Itr scenarios and then used to predict outcomes in an untested Cer + Gem + Itr combination. Results: The model accurately reproduced observed metabolite profiles in single-inhibitor DDIs. Predicted AUCR values for Cer-L were 4.2 (Cer + Gem) and 2.1 (Cer + Itr), with reduced KeM indicating CYP2C8 and CYP3A4 as primary elimination pathways. In the dual-inhibitor scenario, Cer-L AUCR reached ~70—far exceeding that of the parent drug—suggesting severe clearance impairment and toxic accumulation. Conclusions: Dual inhibition of CYP2C8 and CYP3A4 may cause dangerously elevated Cer-L levels, contributing to Cer-associated rhabdomyolysis. This modeling approach offers a powerful framework for evaluating DDI risks involving active or toxic metabolites, supporting safer drug development and regulatory assessment.

Drugs and Drug Candidates doi: 10.3390/ddc4030033

Authors: Adriana de Oliveira Fernandes Valéria Vieira Moura Paixão Yria Jaine Andrade Santos Eduardo Borba Alves Ricardo Pereira Rodrigues Daniela Aparecida Chagas-Paula Aurélia Santos Faraoni Rosana Casoti Marcus Vinicius de Aragão Batista Marcel Bermudez Silvio Santana Dolabella Tiago Branquinho Oliveira

Background/Objectives: Severe malaria, mainly caused by Plasmodium falciparum, remains a significant therapeutic challenge due to increasing drug resistance and adverse effects. Flavonoids, known for their wide range of bioactivities, offer a promising route for antimalarial drug discovery. The aim of this study was to elucidate key structural features associated with antimalarial activity in flavonoids and to develop accurate, interpretable predictive models. Methods: Curated databases of flavonoid structures and their activity against P. falciparum strains and enzymes were constructed. Molecular fingerprinting and decision tree analyses were used to identify key pharmacophoric groups. Subsequently, molecular descriptors were generated and reduced to build multiple classification and regression models. Results: These models demonstrated high predictive accuracy, with test set accuracies ranging from 92.85% to 100%, and R2 values from 0.64 to 0.97. Virtual screening identified novel flavonoid candidates with potential inhibitory activity. These were further evaluated using molecular docking and molecular dynamics simulations to assess binding affinity and stability with Plasmodium proteins (FabG, FabZ, and FabI). The predicted active ligands exhibited stable pharmacophore interactions with key protein residues, providing insights into binding mechanisms. Conclusions: This study provides highly predictive models for antimalarial flavonoids and enhances the understanding of structure–activity relationships, offering a strong foundation for further experimental validation.

Drugs and Drug Candidates doi: 10.3390/ddc4030032

Authors: Meaghan Jones Aryanna Demery Rami A. Al-Horani

Suzetrigine represents a groundbreaking advancement in acute pain management as the first FDA-approved selective Nav1.8 inhibitor. This comprehensive review synthesizes data from clinical trials, pharmacological studies, and prescribing information to evaluate its mechanism, efficacy, safety, and clinical implications. With demonstrated superiority over placebo in pivotal trials (SPID48: 29.3–48.4; p < 0.0001) and a favorable safety profile devoid of opioid-like addiction risks, suzetrigine offers a much-needed alternative in the opioid crisis era. However, its modest effect size compared to full-dose opioids, CYP3A-mediated drug interactions, and limited long-term data warrant judicious use. This article provides a balanced perspective on suzetrigine’s role in modern pain management protocols.

Drugs and Drug Candidates doi: 10.3390/ddc4030031

Authors: Mahathir Mohammad Md. Jahirul Islam Mamun Mst. Maya Khatun Md. Hossain Rasel M Abdullah Al Masum Khurshida Jahan Suma Mohammad Rashedul Haque Sayed Al Hossain Rabbi Md. Hemayet Hossain Hasin Hasnat Nafisah Mahjabin Safaet Alam

Background: Shirakiopsis indica (Willd.) (Family: Euphorbiaceae), a mangrove species found in the Asian region, is a popular folkloric plant. Locally, the plant is traditionally used to treat various types of ailments, especially for pain relief. Therefore, the current study investigates the neuropharmacological, antipyretic, thrombolytic, and anthelmintic properties of the S. indica fruit methanolic extract (SIF-ME). Methods: The neuropharmacological activity was evaluated using several bioactive assays, and the antipyretic effect was investigated using the yeast-induced pyrexia method, both in Swiss albino mice models. Human blood clot lysis was employed to assess thrombolytic activity, while in vitro anthelmintic characteristics were tested on Tubifex tubifex. Insights into phytochemicals from SIF-ME have also been reported from a literature review, which were further subjected to molecular docking, pass prediction, and ADME/T analysis and validated the wet-lab outcomes. Results: In the elevated plus maze test, SIF-ME at 400 mg/kg demonstrated significant anxiolytic effects (200.16 ± 1.76 s in the open arms, p < 0.001). SIF-ME-treated mice exhibited increased head dipping behavior and spent a longer time in the light box, confirming strong anxiolytic activity in the hole board and light–dark box tests, respectively. It (400 mg/kg) also significantly reduced depressive behavior during forced swimming and tail suspension tests (98.2 ± 3.83 s and 126.33 ± 1.20 s, respectively). The extract induced strong locomotor activity, causing mice’s mobility to gradually decrease over time in the open field and hole cross tests. The antipyretic effect of SIF-ME (400 mg/kg) was minimal using the yeast-induced pyrexia method, while it (100 μg/mL) killed T. tubifex in 69.33 ± 2.51 min, indicating a substantial anthelmintic action. SIF-ME significantly reduced blood clots by 67.74% (p < 0.001), compared to the control group’s 5.56%. The above findings have also been predicted by in silico molecular docking studies. According to the molecular docking studies, the extract’s constituents have binding affinities ranging from 0 to −10.2 kcal/mol for a variety of human target receptors, indicating possible pharmacological activity. Conclusions: These findings indicate that SIF-ME could serve as a promising natural source of compounds with neuropharmacological, anthelmintic, thrombolytic, and antipyretic properties.

Drugs and Drug Candidates doi: 10.3390/ddc4030030

Authors: Washington de Souza Leal Juliane Zacour Marinho Isabela Penna Ceravolo Lucas Leão Nascimento Antonio Otávio de Toledo Patrocínio Marcus Vinícius Dias-Souza

Background: Bacterial resistance to antimicrobial drugs is a critical phenomenon that is hampering clinical treatments, raising the need for promising compounds that can be explored as pharmaceutical products. This study investigated the antimicrobial potential of α-Ag2WO4–alpha phase, orthorhombic structure silver tungstate nanoparticles (STN), against clinical isolates of Staphylococcus aureus, Pseudomonas aeruginosa and Escherichia coli, alone and combined to clinically relevant antimicrobial drugs. Methods: We used classical methods (MIC/checkerboard) to investigate the antimicrobial activity of STN. We characterized STN using X-ray diffraction, photoluminescence and scanning electron microscopy. We also performed cytotoxicity tests on BGM cells and anti-inflammatory tests in vitro. Results: STN was effective at 128 µg/mL for S. aureus and at 256 µg/mL for E. coli, but was not effective against P. aeruginosa. When combined with antimicrobials, STN decreased their MIC values, and its anti-inflammatory potential was confirmed. CC50 of STN was of 16.23 ± 1.09 μg/mL against BGM cells. Conclusions: Our data open doors for further studies in animal models to investigate the effects on STN in infectious diseases.

Drugs and Drug Candidates doi: 10.3390/ddc4030029

Authors: David O. Oladejo Titilope M. Dokunmu Gbolahan O. Oduselu Daniel O. Oladejo Olubanke O. Ogunlana Emeka E. J. Iweala

Background: Malaria remains a significant global health burden, particularly in sub-Saharan Africa, accounting for high rates of illness and death. The growing resistance to frontline antimalarial therapies underscores the urgent need for novel drug targets and therapeutics. Bromodomain-containing proteins, which regulate gene expression through chromatin remodeling, have gained attention as potential targets. Plasmodium falciparum bromodomain protein 1 (PfBDP1), a 55 kDa nuclear protein, plays a key role in recognizing acetylated lysine residues and facilitating transcription during parasite development. Methods: This study investigated ex vivo PfBDP1 gene mutations and identified potential small molecule inhibitors using computational approaches. Malaria-positive blood samples were collected. Genomic DNA was extracted, assessed for quality, and amplified using PfBDP1-specific primers. DNA sequencing and alignment were performed to determine single-nucleotide polymorphism (SNP). Structural modeling used the PfBDP1 crystal structure (PDB ID: 7M97), and active site identification was conducted using CASTp 3.0. Virtual screening and pharmacophore modeling were performed using Pharmit and AutoDock Vina, followed by ADME/toxicity evaluations with SwissADME, OSIRIS, and Discovery Studio. GROMACS was used for 100 ns molecular dynamics simulations. Results: The malaria prevalence rate stood at 12.24%, and the sample size was 165. Sequencing results revealed conserved PfBDP1 gene sequences compared to the 3D7 reference strain. Virtual screening identified nine lead compounds with binding affinities ranging from −9.8 to −10.7 kcal/mol. Of these, CHEMBL2216838 had a binding affinity of −9.9 kcal/mol, with post-screening predictions of favorable drug-likeness (8.60), a high drug score (0.78), superior pharmacokinetics, and a low toxicity profile compared to chloroquine. Molecular dynamics simulations confirmed its stable interaction within the PfBDP1 active site. Conclusions: Overall, this study makes a significant contribution to the ongoing search for novel antimalarial drug targets by providing both molecular and computational evidence for PfBDP1 as a promising therapeutic target. The prediction of CHEMBL2216838 as a lead compound with favorable binding affinity, drug-likeness, and safety profile, surpassing those of existing drugs like chloroquine, sets the stage for preclinical validation and further structure-based drug design efforts. These findings are supported by prior experimental evidence showing significant parasite inhibition and gene suppression capability of predicted hits.

Drugs and Drug Candidates doi: 10.3390/ddc4030028

Authors: Ankita Sharma Yen-Che Hsiao Abhishek Dutta

The methods utilized in the drug discovery pipeline routinely combine machine learning and deep learning algorithms to enhance the outputs. The generation of a drug target, through virtual screening and computational analysis of databases used for target discovery, has increased the reliability of the machine learning and deep learning incorporated techniques. Recent technological advances in human immunology have provided improved tools that allow a better understanding of the biological and molecular mechanisms leading to the protective human immune response to pathogens, inspiring new strategies for vaccine design. Immunoinformatics approaches are more beneficial, and thus there is a demand for modern technologies such as reverse vaccinology, structural vaccinology, and system approaches in developing potential vaccine candidates. System theory, defined as a set of machine learning, control theory, and optimization-based methods applied to networked systems, provides a unifying framework for modeling and analyzing biological complexity. In this review, we explore the application of such computational methods at every stage of the therapeutic pipeline, including lead discovery, optimization, and dosing, as well as vaccine target prediction and immunogen design. Here, we summarize the system theoretic methods which provide insights into developed approaches and their applications in rational drug discovery and vaccine formulations. The approaches ranged in the review yield accurate predictions and insights. This review is intended to serve as a resource for researchers seeking to understand, adopt, or build upon system theoretic techniques in drug and vaccine development, offering both conceptual foundations and practical directions.

Drugs and Drug Candidates doi: 10.3390/ddc4020027

Authors: Brendo Araujo Gomes Diégina Araújo Fernandes Thamirys Silva da Fonseca Mariana Freire Campos Patrícia Alves Jural Marcos Vinicius Toledo e Silva Larissa Esteves Carvalho Constant Andrex Augusto Silva da Veiga Beatriz Ribeiro Ferreira Ellen Santos Magalhães Hagatha Bento Mendonça Pereira Beatriz Graziela Martins de Mattos Beatriz Albuquerque Custódio de Oliveira Stephany da Silva Costa Flavia Maria Mendonça do Amaral Danilo Ribeiro de Oliveira Ivana Correa Ramos Leal Gabriel Rocha Martins Gilda Guimarães Leitão Diego Allonso Simony Carvalho Mendonça Marcus Tullius Scotti Suzana Guimarães Leitão

Background/Objectives: Since the emergence of the COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the discovery of compounds with antiviral potential from medicinal plants has been extensively researched. This study aimed to investigate plant metabolites with in vitro inhibitory potential against SARS-CoV-2 targets, including 3CLpro, PLpro, Spike protein, and RdRp. Methods: A systematic review was conducted following PRISMA guidelines, with literature searches performed in six electronic databases (Scielo, ScienceDirect, Scopus, Springer, Web of Science, and PubMed) from January 2020 to February 2024. Computational analyses using SwissADME, pkCSM, ADMETlab, ProTox3, Toxtree, and DataWarrior were performed to predict the absorption, distribution, metabolism, excretion, and toxicity (ADMET) profiles as well as other medicinal chemistry parameters of these compounds. Results: A total of 330 plant-derived compounds with inhibitory activities against the proposed targets were identified, with compounds showing IC50 values as low as 0.01 μM. Our findings suggest that several plant metabolites exhibit significant in vitro inhibition of SARS-CoV-2 targets; however, few molecules exhibit drug development viability without further adjustments. Additionally, after these evaluations, two phenolic acids, salvianic acid A and protocatechuic acid methyl ester, stood out for their potential as candidates for developing antiviral therapies, with IC50 values of 2.15 μM against 3CLpro and 3.76 μM against PLpro; respectively; and satisfactory in silico drug-likeness and ADMET profiles. Conclusions: These results reinforce the importance of plant metabolites as potential targets for antiviral drug discovery.

Drugs and Drug Candidates doi: 10.3390/ddc4020026

Authors: Mokete Motente Uche A. K. Chude-Okonkwo

Background: One of the challenges of applying artificial intelligence (AI) methods to drug discovery is the difficulty of laboratory synthesizability for many AI-discovered molecules. Often, in silico techniques and metrics such as the computationally enabled synthesizability score and AI-based retrosynthesis analysis are used. Methods: In this paper, we present a predictive synthesizability method that integrates the gains of synthetic accessibility scoring and the benefits of AI-driven retrosynthesis analysis tools to evaluate the synthesizability of AI-generated lead drug molecules. Results: We explored the proposed method by using it to analyze the synthesizability of a set of 123 novel molecules generated using AI models. The analysis of the synthesis route of the four best molecules from the set in terms of synthesizability, as identified using the proposed method, is presented. Conclusions: This strategy enables quick initial screening and more comprehensive actionable synthetic pathways, thereby balancing speed and detail, and favoring simple routes to avoid the risk of pursuing non-synthesizable compounds in the drug development pipeline.

Drugs and Drug Candidates doi: 10.3390/ddc4020025

Authors: Sandra Gunne Fiona K. Sailer Lucas Keutmann Marie Schwerdtner Hong M. Moulton Eva Böttcher-Friebertshäuser Susanne Schiffmann

Background: TMPRSS2 plays an important role in the viral entry mechanisms of influenza viruses and coronaviruses. Therefore, TMPRSS2 seems to be a suitable antiviral drug target. To exclude possible side effects of TMPRSS2 truncation in an early stage of drug in-vitro testing, this study aims to analyze the impact of TMPRSS2 truncation via antisense peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) targeting immune cells, using the example of regulatory T cells (Treg). Methods: TMPRSS2 was truncated in human Tregs using a splice-modulating PPMO. Effects on Treg function were analyzed by evaluation of surface marker and transcription factor expression, cytokine secretion, and effector cell suppression capability. Results: PPMO treatment led to a slight concentration-dependent toxicity in Tregs. Tregs with truncated TMPRSS2 behave similarly to untreated and control PPMO-treated cells in the analyzed assays. Conclusions: Treg function is not altered after TMPRSS2 truncation and therefore, no unwanted side effects in regard of Tregs are expected when using TMPRSS2-truncating PPMO as an anti-viral drug.

Drugs and Drug Candidates doi: 10.3390/ddc4020024

Authors: Martin Kondža Josipa Bukić Ivan Ćavar Biljana Tubić

Cytochrome P450 (CYP450) enzymes are pivotal in the metabolism of numerous anticancer agents, with CYP3A4 being the predominant isoform involved. Inhibition of CYP450 enzymes is a major mechanism underlying clinically significant drug-drug interactions (DDIs), particularly in oncology, where polypharmacy is frequent. This review aims to provide a comprehensive and critical overview of CYP450 enzyme inhibition, focusing specifically on the impact of kinase inhibitors (KIs) and poly adenosine diphosphate-ribose polymerase (PARP) inhibitors. A systematic review of the current literature was conducted, focusing on the molecular mechanisms of CYP450 inhibition, including reversible, time-dependent, mechanism-based, and pseudo-irreversible inhibition. Specific attention was given to the inhibitory profiles of clinically relevant KIs and PARP inhibitors, with analysis of pharmacokinetic consequences and regulatory considerations. Many KIs, such as abemaciclib and ibrutinib, demonstrate time-dependent or quasi-irreversible inhibition of CYP3A4, while PARP inhibitors like olaparib and rucaparib exhibit moderate reversible and time-dependent CYP3A4 inhibition. These inhibitory activities can significantly alter the pharmacokinetics of co-administered drugs, leading to increased risk of toxicity or therapeutic failure. Regulatory guidelines now recommend early identification of time-dependent and mechanism-based inhibition using physiologically based pharmacokinetic) (PBPK) modeling. CYP450 inhibition by KIs and PARP inhibitors represents a critical but often underappreciated challenge in oncology pharmacotherapy. Understanding the mechanistic basis of these interactions is essential for optimizing treatment regimens, improving patient safety, and supporting personalized oncology care. Greater clinical vigilance and the integration of predictive modeling tools are necessary to mitigate the risks associated with CYP-mediated DDIs.

Drugs and Drug Candidates doi: 10.3390/ddc4020023

Authors: Anchal Dubey Bechan Sharma

Breast cancer continues to represent one of the most widespread and lethal health afflictions on a global scale. The advancement of this malignancy is predominantly influenced by genetic mutations that precipitate unregulated cellular growth and proliferation, with oxidative stress being a crucial factor in all phases of carcinogenic development. Oxidative stress emerges from a disruption in the equilibrium between reactive oxygen species (ROS) and antioxidants, which inflicts damage on cellular components and facilitates the onset of cancer. Although numerous studies have advocated the notion that augmenting antioxidant levels may confer protection against cancer, other investigations have yielded contradictory results. Nevertheless, the effectiveness of antioxidants in cancer prophylaxis remains contentious, with research exhibiting variable outcomes. Certain studies have indicated that a high consumption of fruits and vegetables abundant in antioxidants may lower cancer risk. However, the irrefutable evidence is currently absent. Furthermore, the chemotherapeutic agents, such as taxanes and cisplatin, utilized in breast cancer management are reported to produce ROS as an integral aspect of their therapeutic mechanisms, thereby highlighting the intricate interplay between redox equilibrium and oncological treatment. This review emphasizes the pro-oxidant hypothesis, which asserts that heightened levels of ROS may selectively annihilate cancer cells, given that normal cells generally sustain low levels of ROS. Some recent reports have indicated that the application of plant-based molecules as a therapeutic supplement may help treat breast cancer effectively. However, a comprehensive understanding of the role of oxidative stress in breast cancer and use of antioxidants could pave the way for more precisely targeted therapeutic strategies aimed at the modulation of redox homeostasis.

Drugs and Drug Candidates doi: 10.3390/ddc4020022

Authors: Nagaraju Bandaru Sarad Pawar Naik Bukke Veera Mani Deepika Pedapati Gurugubelli Sowjanaya Vangmai Swaroopa Suggu Swathi Nalla Prashik Bhimrao Dudhe Joseph Obiezu Chukwujekwu Ezeonwumelu Abdullateef Isiaka Alagbonsi Hope Onohuean

Current treatment options for Alzheimer’s disease target neurotransmitters following the disease onset, and they offer limited efficacy without slowing down the disease progression. There has been an increasing concern in recent years targeting the histamine H3 receptor (H3R) in treating cognitive disorders, including dementia. Preclinical studies have shown that antagonists of H3R or inverse agonists enhance the cognitive function in animal models with dementia by increasing the release of neurotransmitters associated with learning and memory. This review employed a systematic literature search across databases including PubMed, Scopus, Google Scholar, and ClinicalTrials.gov, selecting peer-reviewed studies. The results of this study illustrate the complex landscape of research on H3R modulators in dementia, highlighting both promising findings and ongoing challenges in translating preclinical discoveries into effective clinical interventions. Knowing the role of H3R in dementia and developing novel pharmacological interventions targeting these receptors represent a promising avenue for future research, leading to the development of new treatments for this devastating condition.

Drugs and Drug Candidates doi: 10.3390/ddc4020021

Authors: Pedro Alcântara Henrique Siqueira Anwar Shamim Denise Gonçalves Priolli Karine C. Q. Banagouro Hélio A. Stefani Juliana Mozer Sciani

Background/Objectives: Pancreatic cancer is the seventh most lethal type of cancer in the world, and its treatment, which is largely inefficient, is based on surgery and/or non-specific chemotherapy. Its malignant features are characterized by complex cell signaling pathways, which can be used as targets for new drugs. Methods: In this study, glucal-based compounds were synthetized, with substitution based on fluorine, nitrogen and aromatic ring addition. The compounds were tested in the pancreatic cell culture Mia-PaCa-2 and cell viability was assessed, with further IC50 calculation, stability and selectivity. Molecular docking was performed to evaluate the probable molecular target for 5b and in silico physicochemical properties were determined. Results: One molecule, named 5b, with two fluorine atoms inserted in the aromatic ring, exerted potent inhibitory activity on cell growth (IC50 = 1.39 µM), which was selective for pancreatic cells. Through molecular docking studies, the compound was found to be positioned in the active site of JAK3, indicating inhibition of such protein, which has a role in tumoral cell growth. Moreover, 5b was stable for 24 months and had physicochemical properties to permeate cell membranes, good oral absorption, and low potential to cause toxicity. Conclusions: These data suggest that 5b can be druggable and can be considered as a prototype for a new course of treatment in pancreatic cancer.

Drugs and Drug Candidates doi: 10.3390/ddc4020020

Authors: Hüseyin Oğuzhan Kaya Ceylin Bozdemir Hüseyin İstanbullu Seda Nur Topkaya

Background/Objectives: The thiazolo [5,4-d]pyrimidine scaffold is a class of drugs known for its anticancer, antitumor, anti-inflammatory, and antimicrobial properties. In this study, the electrochemical properties of novel thiazolo [5,4-d]pyrimidine derivatives and their interactions with DNA were characterized for the first time using voltammetric methods. Determining the interactions of new drug candidate molecules with DNA is crucial for drug development studies and is the main objective of this research. Methods: Both molecules were immobilized on the surface of the electrodes by passive adsorption, and their electrochemical properties were determined by voltammetric methods through reduction currents. Their interactions with DNA were carried out in the solution phase and examined by the changes in the oxidation peak potential and current of the guanine base. Results: For both molecules, it was determined that the electrochemical reduction processes are diffusion-controlled and irreversible, with an equal number of protons and electrons being transferred during this process. The detection limits for TP-NB (4-chloro-N-(5-chlorothiazolo [5,4-d]pyrimidin-2-yl)-3-nitrobenzamide) and TP-PC (1-(2-(4-(4-carbamoylpiperidin-1-yl)-3-nitrobenzamido)thiazolo [5,4-d]pyrimidin-5-yl)piperidine-4-carboxamide) were determined to be 12 µg/mL and 16 µg/mL, respectively. As a result of the interaction between both molecules with DNA, the guanine oxidation current decreased. It was found that TP-NB could act as an intercalator, while TP-PC could affect DNA electrostatically, both showing toxic effects on DNA. Conclusions: An electrochemical method was developed for the rapid, cost-effective, and sensitive detection of both molecules and their DNA interactions. Both compounds exhibited notable affinity towards DNA, as evidenced by significant changes in oxidation peak currents, shifts in peak potentials, and calculated toxicity values. These findings suggest their potential use as DNA-interacting drugs, such as anticancer and antimicrobial agents. Our study offers a quick, cost-effective, and reliable electrochemical approach for the evaluation of drug–DNA interactions.

Drugs and Drug Candidates doi: 10.3390/ddc4020019

Authors: Tanvi Premchandani Amol Tatode Jayshree Taksande Milind Umekar Mohammad Qutub Ujban Md Hussain Priyanka Singanwad

Engineered exosomes have emerged as transformative drug carriers, uniquely equipped to overcome biological barriers in central nervous system (CNS) disorders and cancer therapy. These natural extracellular vesicles, derived from cell membranes, offer inherent biocompatibility, low immunogenicity, and the ability to traverse physiological obstacles such as the blood–brain barrier (BBB) and dense tumor stroma. Recent advances in exosome engineering—including surface modification (e.g., ligand conjugation for receptor-mediated targeting) and cargo loading (siRNA, CRISPR-Cas systems, and chemotherapeutics)—have enhanced their precision and therapeutic utility. For CNS delivery, exosomes functionalized with brain-homing peptides (e.g., RVG or TfR ligands) have enabled the efficient transport of neuroprotective agents or gene-editing tools to treat Alzheimer’s disease or glioblastoma. In oncology, engineered exosomes loaded with tumor-suppressive miRNAs or immune checkpoint inhibitors exploit tumor microenvironment (TME) features, such as acidity or enzyme overexpression, for spatially controlled drug release. Furthermore, hybrid exosome–liposome systems and exosome–biomaterial composites are being explored to improve payload capacity and stability. Despite progress, challenges persist in scalable production, batch consistency, and regulatory standardization. This review critically evaluates engineering strategies, preclinical success, and translational hurdles while proposing innovations such as AI-driven exosome design and patient-derived exosome platforms for personalized therapy. By bridging nanotechnology and biomedicine, engineered exosomes can represent a paradigm shift in targeted drug delivery, offering safer and more effective solutions for historically intractable diseases.

Drugs and Drug Candidates doi: 10.3390/ddc4020018

Authors: Patricia Dolores Martinez-Flores Marisol Gastelum-Cabrera Manuel G. Ballesteros-Monrreal Pablo Mendez-Pfeiffer Marco Antonio Lopez-Mata Gerardo García-González Gerardo Erbey Rodea-Montealegre Josué Juárez

Background/Objectives: Bacterial infections remain among the top ten major public health concerns, contributing to a high number of incidences of disease and mortality worldwide, exacerbated by the rise of multidrug-resistant bacteria (MDRB). Consequently, it is crucial to develop novel antimicrobial strategies, including the use of functional nanoparticles. Gold nanoparticles (GNPs) have emerged as promising candidates due to their unique optical properties, particularly their ability to efficiently convert absorbed light into heat through the photothermal (PT) effect, which can be harnessed for bacteria eradication. Methods: Chitosan was modified with 3-mercaptopropionic acid to introduce sulfur groups, facilitating gold deposition onto chitosan nanoparticle (TCNPs) surface. The gold shell was subsequently formed via a seed-mediated method, wherein gold seeds were adsorbed onto TCNPs and further grown to form the shell. Photothermal effect on the bacterial viability was evaluated. Results: TCNPs with a size of 178 nm and spherical morphology were obtained. After the gold shell (TCNP@Au) exhibited a photothermal conversion efficiency of 31%, making them a promising photothermal agent for bacterial clearance. Notably, the viability of Escherichia coli was significantly reduced in the presence of TCNP@Au and was almost eradicated upon PT treatment. In contrast, TCNP@Aus were non-toxic for Staphylococcus aureus. Conclusions: TCNP@Au demonstrated favorable photothermal properties, presenting a novel nanoplatform for antibacterial applications, particularly against Gram-negative bacteria. However, further investigation is required to optimize the PT-based strategies against Gram-positive bacteria, such as S. aureus.

Drugs and Drug Candidates doi: 10.3390/ddc4020017

Authors: Priyanka Kumari Manish Kumar Shukla Ashutosh Tripathi Janmejay Pandey Amit K. Goyal

Background: Metritis, a common postpartum uterine infection in bovines, poses substantial challenges in livestock management, including compromised fertility and economic losses. Poor uterine drug penetration and systemic side effects, necessitating innovative localised delivery systems and limiting current systemic antibiotic treatments. Aim: This study aimed to develop and evaluate the potential effect of the ofloxacin-loaded hydrogel as a localised drug delivery system to treat metritis in bovine. The focus was on achieving sustained drug release, enhanced antibacterial efficacy and reduced inflammation in the endometrium. Materials and Methods: The CS/PVA hydrogel was synthesised using a freeze–thaw method and further optimised for drug encapsulation efficiency (96.7 ± 2.1%), stability and biocompatibility. Physicochemical characterisation included swelling behaviour, mechanical properties and rheological analysis. In vitro drug release profiles in the simulated uterine fluid were assessed over 72 h and antibacterial activity was tested against common uterine pathogens such as Escherichia coli and S. aureus. In vivo studies were conducted on bovines diagnosed with endometritis to evaluate clinical recovery. Results: The SEM image of the ofloxacin-loaded CS/PVA hydrogel resulted in a smooth and porous structure demonstrating larger pore size than the blank. The rheological study suggested higher stability and elastic behaviour. Antibacterial assays on E. coli and S. aureus revealed significant inhibition zones, respectively, indicating potent efficacy. In vivo, evaluated on treated bovine, reduced bacterial loads were exhibited (2.86 × 105A CFU/mL → 6.37 × 102B CFU/mL), clinical improvement was marked and uterine inflammation was resolved. Conclusions: Ofloxacin-loaded hydrogels represent a promising localised treatment for bovine metritis, offering sustained antibacterial action and improved clinical outcomes. This approach addresses the limitations of systemic antibiotic therapies and provides a practical solution for enhanced veterinary care. Further studies are recommended to validate these findings in more extensive field trials and explore commercialisation potential.

Drugs and Drug Candidates doi: 10.3390/ddc4020016

Authors: Sujatha Lokanath Manjunatha Katagi Girish Bolakatti Johnson Samuel Belakatte Nandeshwarappa

Background: The cholinergic hypothesis is an elementary approach employed for the research and drug discovery of novel anti-Alzheimer therapeutics. Method: In this context, the study focuses on synthesizing and evaluating a new series of chalcone derivatives (3a–3j) as multifunctional therapeutic agents, specifically investigating their antioxidant potential using the DPPH method with ascorbic acid as a standard. Ellman’s protocol for acetylcholinesterase inhibition assay was performed using donepezil as a standard, and computational insights were explored through molecular docking and ADME profiling. Results: Compounds 3a, 3d, 3e, 3f, and 3h exhibited excellent antioxidant activity compared to the standard. Most of the compounds exhibited moderate to good (3b, 3c, and 3h) AChE inhibitory activity. Molecular docking studies revealed conventional hydrogen bonding and π-π interactions with the enzyme’s active residues, facilitated by their electronegative groups and phenyl rings, respectively. In addition, a pharmacokinetic study was conducted using computational approach to assess druggability. The results demonstrated that compound 3b is an outstanding lead candidate with appreciable AChE inhibitory activity. Conclusions: The combined experimental and computational results of this study highlight the multifunctional nature of chalcone derivatives, suggesting their potential as promising therapeutic agents for the discovery of novel AChE inhibitors that could be employed in the management of Alzheimer’s disease and oxidative stress-related diseases.

Drugs and Drug Candidates doi: 10.3390/ddc4020015

Authors: Preeti Gupta

To date, numerous studies have emerged that indicate the possible role of epigenetic modulation in the development and progression of several diseases, including cancer. Epigenetic alterations participate in various steps of carcinogenesis. They play important regulatory roles in processes like cell division, proliferation, angiogenesis, and metastasis. Thus, epigenetic modifications such as DNA methylation, histone modifications, and non-coding RNAs serve as attractive and promising targets for cancer prevention and anti-cancer therapy. Epigenetic drugs or epi-drugs possess the ability to reverse many such epigenetic alterations and thus can help manage the clinical manifestations of cancer. Epigenetic drugs broadly target epigenetic modifications, including DNA methylation and histone post-translational modifications, to manifest their effects. Several naturally occurring as well as chemically synthesized compounds have been recognized as epigenetic drugs. Some of them are clinically approved, while many are in their preclinical and clinical trials. In this review, we aim to present a broad overview of the epigenetic modifications implicated in carcinogenesis. The review also compiles various epigenetic drugs that are approved for clinical practice, as well as those that are in the preclinical and clinical stages of investigation for anti-cancer therapy.

Drugs and Drug Candidates doi: 10.3390/ddc4020014

Authors: Sarah Scoles Sanjay Ganesh Kaori H. Yamada

Background/Objectives: Uveal melanoma (UM) is a rare but deadly ocular cancer. This review summarizes the characteristics of uveal melanoma and current therapeutic options for primary uveal melanoma and metastatic uveal melanoma, and introduces recent development of therapeutic strategies in preclinical animal studies and clinical trials. Methods: The literature search was conducted to identify relevant articles for UM studies. It was performed using PubMed for articles in English until March 2025. Information on clinical trials was also obtained from ClinicalTrial.gov. Results: Uveal melanoma originates from melanocytes, similar to skin melanoma. However, uveal melanoma has different mutations from skin melanoma. Thus, chemotherapy and immunotherapy, which are effective for skin melanoma, are ineffective for uveal melanoma. Current therapies for UM include radiation therapy, surgical resection, liver-directed therapies, and recently FDA-approved tebentafusp. Although a wide variety of available and newly developed therapies have been tested in clinical trials for UM, tebentafusp is the only FDA-approved therapy for metastatic UM. Given the excessive expression of vascular endothelial growth factor (VEGF) in UM patients with metastatic diseases, anti-VEGF strategies are being tested in clinical trials and pre-clinical animal models. Conclusions: This review summarizes an overview of current therapies and the development of therapeutic strategies in clinical trials and pre-clinical animal models. Despite successful control of primary tumors, 50% of UM patients still experience metastasis in the liver. Although tebentafusp improves the overall survival (OS) of a certain population of UM patients, robust strategies for preventing UM metastasis represent a critical unmet need. Further investigations of the heterogeneity of UM cells and mechanisms of UM metastasis are needed in the future.

Drugs and Drug Candidates doi: 10.3390/ddc4020013

Authors: Zheng Yao Low Siau Wui Chin Sharifah Syed Hassan Wee Sim Choo

The COVID-19 pandemic, driven by the high transmissibility and immune evasion caused by SARS-CoV-2 and its variants (e.g., Alpha, Delta, Omicron), has led to massive casualties worldwide. As of November 2024, the International Committee on Taxonomy of Viruses (ICTV) has identified 14,690 viral species across 3522 genera. The increasing infectious and resistance to FDA and EMA-approved antivirals, such as 300-fold efficacy reduction in Nirmatrelvir against the SARS-CoV-2 3CLpro, highlight the need for mutation-stable antivirals, likewise targeting the essential host proteins like kinases, heat shock proteins, lipid metabolism proteins, immunological pathway proteins, etc. Unlike direct-acting antivirals, HDAs reduce the risk of resistance by targeting conserved host proteins essential for viral replication. The proposal for repurposing current FDA-approved drugs for host-directed antiviral (HDA) approach is not new, such as the Ouabain, a sodium-potassium ATPase inhibitor for herpes simplex virus (HSV) and Verapamil, a calcium channel blocker for influenza A virus (IAV), to name a few. Given the colossal potential of the mutation-stable HDA approach to exterminate the virus infection, it has been increasingly studied on SARS-CoV-2. This review aims to unravel the interaction between viruses and human hosts and their successfully proposed host-directed antiviral approach to provide insight into an alternative treatment to the rampant mutation in SARS-CoV-2. The benefits, limitations, and potential of host protein-targeted antiviral therapies and their prospects are also covered in this review.

Drugs and Drug Candidates doi: 10.3390/ddc4010012

Authors: Tanja V. Soldatović

The mini-review highlights the innovative development of hetero-dinuclear metallic complexes, with a specific focus on zinc(II) metal centers arranged in a square-pyramidal configuration. The work presented, stemming from our research group in collaboration with others between the years 2020 and 2024, makes significant contributions to this area, emphasizing their potential applications in bioinorganic chemistry, particularly in the context of drug discovery. These advances not only expand the fundamental understanding of such complexes but also lay the groundwork for the design of novel hetero-dinuclear metallic compounds with therapeutic potential. The interaction of these complexes with biological systems and their implications for drug development are critical for future research in bioinorganic chemistry, offering new pathways for targeted treatments and molecular therapies.

Drugs and Drug Candidates doi: 10.3390/ddc4010011

Authors: Pedro Carvalho Araújo Carolina Chaves Ramos Daniela Barros de Oliveira

Background/Objectives: Sleep is essential to human health, playing a vital role in physical and mental well-being. Sleep disorders can lead to significant health complications, such as cardiovascular problems, diabetes, obesity, and depression. In Brazil, plants such as passionflower (Passiflora spp.), chamomile (Matricaria chamomilla L.) and mulungu (Erythrina spp.) are widely used in folk medicine for their sleep-promoting properties. This article reviews the existing literature on the sleep-promoting effects of these plants, focusing on the Brazilian context and popular knowledge of their use. Methods: An integrative literature review was conducted, including scientific articles in English and Portuguese from PubMed, Scielo and Google Scholar databases. Ethnobotanical studies documenting the traditional use of these plants in Brazil and clinical and preclinical research on their sleep-promoting effects were included. Results: The juice and infusion of the leaves and fruits of passionflower are mainly used to treat anxiety and insomnia, chamomile flower tea is used for its sedative effects, and mulungu bark decoctions are used for their sedative and anxiolytic properties. These popular uses are supported by scientific studies demonstrating the efficacy of these plants in treating insomnia, anxiety, and stress. Conclusions: The recognition of traditional knowledge and the inclusion of these plants in RENISUS highlights their importance for public health in Brazil. However, more rigorous clinical trials are needed to confirm their efficacy and safety and ensure their safe integration into modern medicine.

Drugs and Drug Candidates doi: 10.3390/ddc4010010

Authors: Sohaib Khatib Cecilia Faraloni Latifa Bouissane

Tanacetum balsamita is a perennial medicinal plant belonging to the Asteraceae family. The species bears a long history as a valuable traditional drug in different cultures, while it is an essential component in the traditional cuisine of several countries. In this context, our literature review aims at providing a comprehensive overview of T. balsamita, covering its traditional uses, phytochemistry, biological activities, and toxicity from 1983 to 2024. Methods: Various databases were used to collect the information, including Scopus, Science Direct, Google Scholar, PubMed, and Web of Science. Results and conclusions: Although many of its traditional uses have gradually faded into obscurity over the centuries, recent decades have rekindled the interest in this species. Recent ethnobotanical surveys have reported the use of this species against various health-related conditions, while current pharmacological studies have corroborated several health benefits of the species, such as antioxidant, antidiabetic, anti-hyperpigmentation, anticancer, and antimicrobial activities. The validated properties are mainly attributed to the presence of multiple phytoconstituents belonging to flavonoids, phenolic acids, terpenes, and fatty acids, which could also indicate potential uses for T. balsamita in the food industry as a natural preservative and flavoring agent of food products.

Drugs and Drug Candidates doi: 10.3390/ddc4010009

Authors: Priyanka Kandhare Mrunal Kurlekar Tanvi Deshpande Atmaram Pawar

Background/Objectives: The integration of Artificial Intelligence (AI) and Machine Learning (ML) in pharmaceutical research and development is transforming the industry by improving efficiency and effectiveness across drug discovery, development, and healthcare delivery. This review explores the diverse applications of AI and ML, emphasizing their role in predictive modeling, drug repurposing, lead optimization, and clinical trials. Additionally, the review highlights AI’s contributions to regulatory compliance, pharmacovigilance, and personalized medicine while addressing ethical and regulatory considerations. Methods: A comprehensive literature review was conducted to assess the impact of AI and ML in various pharmaceutical domains. Research articles, case studies, and industry reports were analyzed to examine AI-driven advancements in predictive modeling, computational chemistry, clinical trials, drug safety, and supply chain management. Results: AI and ML have demonstrated significant advancements in pharmaceutical research, including improved target identification, accelerated drug discovery through generative models, and enhanced structure-based drug design via molecular docking and QSAR modeling. In clinical trials, AI streamlines patient recruitment, predicts trial outcomes, and enables real-time monitoring. AI-driven predictive maintenance, process optimization, and inventory management have enhanced efficiency in pharmaceutical manufacturing and supply chains. Furthermore, AI has revolutionized personalized medicine by enabling precise treatment strategies through genomic data analysis, biomarker discovery, and AI-driven diagnostics. Conclusions: AI and ML are reshaping pharmaceutical research, offering innovative solutions across drug discovery, regulatory compliance, and patient care. The integration of AI enhances treatment outcomes and operational efficiencies while raising ethical and regulatory challenges that require transparent, accountable applications. Future advancements in AI will rely on collaborative efforts to ensure its responsible implementation, ultimately driving the continued transformation of the pharmaceutical sector.

Drugs and Drug Candidates doi: 10.3390/ddc4010008

Authors: Rayssa F. Franco Paula C. Jimenez

Background/Objectives: This systematic review explores the utilization of electrospinning for the incorporation of natural compounds, focusing on their pharmacological applications. Methods: This systematic review focused on studies investigating the incorporation of natural bioactive compounds into nanofibers produced via the electrospinning technique for pharmacological applications. The search was conducted for English-language articles published online between 1 January 2013 and 10 December 2023. The review followed a structured approach, excluding review articles, clinical studies, and gray literature such as unpublished works, non-peer-reviewed journals, theses, and industry data. Results: The review of 99 articles highlighted the advantages of electrospun nanofibers in tissue regeneration, infection control, and controlled drug release, with notable potential in oncology for targeted antitumor drug delivery. It discussed the influence of polymers and solvents on fiber characteristics and identified a significant gap in cosmetic applications, emphasizing the technique’s potential for prolonged release and improved ingredient stability. Additionally, this review noted the underutilization of marine-derived substances, which possess rich bioactive properties that could benefit biomedical and cosmetic fields. Conclusions: This systematic review highlights the advantages of electrospinning for pharmacological applications, including tissue regeneration, infection control, and controlled drug release, with promising potential in oncology. However, gaps were identified in the cosmetic field and the use of marine-derived substances. Future advancements in electrospinning technology and interdisciplinary collaboration are essential to unlocking its full potential in medicine and cosmetics.

Drugs and Drug Candidates doi: 10.3390/ddc4010007

Authors: Min Chen Hua Zhang Pengfei Ji

Nicotinamide adenine dinucleotide (NAD+) is one of the most essential coenzymes that is widely distributed in human tissues. However, with the progress of aging, the NAD+ level gradually decreases, thus impacting the metabolic dynamics and heightening susceptibility to various pathologies. Increasing NAD+ levels are expected to delay aging and improve age-related degenerative diseases. Amino–carboxylic semialdehyde dehydrogenase (ACMSD) is a key enzyme involved in the de novo synthesis of NAD+. It reduces the intermediate products of the de novo synthesis pathway by catalyzing the degradation of α-amino-β-carboxyethylglutamic acid-ε-semialdehyde (ACMS), thus reducing the production of NAD+. Genetic and pharmacological inhibition of ACMSD has been demonstrated to increase NAD+ levels in vitro and in vivo, thus making it a potential target for the treatment of NAD+-deficient diseases. In this mini-review, we detail the molecular mechanisms regulated by ACMSD. We also discuss the potential efficacy and progress of ACMSD inhibitors in treating aging and age-related diseases.

Drugs and Drug Candidates doi: 10.3390/ddc4010006

Authors: Carlos Jiménez-Romero Luis A. Amador Gabriel Castro-Falcón Abimael D. Rodríguez

Background/Objectives: The marine sponge Plakortis halichondrioides is notable for its capacity to accumulate a large array of secondary metabolites. The present research aims at discovering new secondary metabolites from P. halichondrioides with potential applications in medicine. Methods: Plakortilactone (1) and seco-plakortide F acid (2), two new polyketides, along with known manadodioxan D (3), 13-oxo-plakortide F (4), plakortide F (5), and manadodioxan E (6), were isolated from P. halichondrioides. We achieved the structural elucidation of 1 and 2 using modern spectroscopic methods. The relative stereochemistry of 1 was proposed on the basis of 1D- and 2D-NMR data in combination with molecular modeling studies. Additionally, the absolute configuration of 2 was established through chemical correlation to 5. We screened some of the isolated compounds against the malaria parasite Plasmodium falciparum 3D7 non-resistant (wild-type resistant) strain, the tuberculosis bacterium Mycobacterium tuberculosis, the prostate cancer cell line DU-145, and the melanoma cell line A-2058. Results: minimal activity was detected for 2 against these cancer cells. In contrast, 3 and 4 displayed activity against DU-145 cells with IC50 values of 1.6 µg/mL and 4.5 µg/mL, respectively, and A-2058 cells with IC50s of 2.6 µg/mL and 7.7 µg/mL, respectively. In the antiplasmodial activity assay 3 appeared more active (IC50 = 1.7 µg/mL) than 4 (IC50 = 3.1 µg/mL). Meanwhile, 2 displayed only moderate activity (IC50 = 39.3 µg/mL). In the antimycobacterial activity assay 2 exhibited moderate inhibition (MIC = 75.1 µg/mL). In contrast, a 1:1 mixture of 3 and 4 demonstrated higher activity (MIC = 26.3 µg/mL). Conclusions: the biological activity data together with ADMET predictions indicated favorable pharmacokinetic properties for 3.

Drugs and Drug Candidates doi: 10.3390/ddc4010005

Authors: Seyede Tabatabaei Zahra Keykhaee Saghi Nooraei Mohammad Ayati Mohammad Behzadmand Saba Azimi Fatemeh Eskati Gholamreza Ahmadian

COVID-19, first identified in December 2019 in Wuhan, China, is caused by the SARS-CoV-2 virus, a pathogen that primarily targets the respiratory system and can lead to severe conditions such as acute respiratory distress syndrome (ARDS). Among the seven coronaviruses known to infect humans, three—SARS-CoV, MERS-CoV, and SARS-CoV-2—are associated with severe illness and significant morbidity. SARS-CoV-2 is an enveloped, single-stranded RNA virus that utilizes the angiotensin-converting enzyme 2 (ACE2) receptor for cellular entry. The genetic sequence of SARS-CoV-2 is highly mutable, leading to the emergence of variants that alter disease pathology and transmission dynamics. The World Health Organization (WHO) has classified these mutations into variants of concern (VOCs), variants of interest (VOIs), and variants under monitoring (VUMs). This review provides an in-depth analysis of both historical and emerging SARS-CoV-2 variants, summarizes recent advancements in diagnostic methods for SARS-CoV-2 detection, and discusses current therapeutic strategies for COVID-19, with a particular focus on virus-like particle (VLP) vaccines developed in recent years. Additionally, we highlight ongoing therapeutic approaches and their implications for managing COVID-19.

Drugs and Drug Candidates doi: 10.3390/ddc4010004

Authors: Noureddine Chaachouay

Background/Objectives: The interaction of bioactive compounds derived from plants with drugs has become a significant area of investigation due to its potential to improve, reduce, or have no effect on therapeutic outcomes. Due to the dual effect of these interactions, elucidating the underlying mechanisms is essential for establishing a therapeutic strategy. This study emphasizes the significant findings, mechanisms, and clinical implications of drug–plant bioactive interactions. It calls for more studies to seek safe and effective incorporation into clinical practice. Methods: To identify relevant studies, we performed a systematic literature search based on various scientific databases from 11 August 2024 to 30 December 2024. The search will be based on relevant keywords such as synergy, antagonism, plant bioactive compounds, and drug interactions supplemented with secondary terms such as phytochemicals, herb-drug interactions, pharmacokinetics, and pharmacodynamics. Results: Plant bioactives, including polyphenols, flavonoids, alkaloids, and terpenoids, display valuable biological activities that can interact with medications in three principal ways: synergy, additive effects, and antagonism. Synergy occurs when the combined effects of plant chemicals and pharmaceuticals outweigh the sum of their separate effects, increasing therapeutic effectiveness or allowing dosage decrease to reduce adverse effects. Additive effects occur when the combined impact equals the total individual effects, resulting in better outcomes without increasing risk. Antagonism occurs when a plant ingredient reduces or counteracts the effects of a medicine, thereby jeopardizing treatment. In addition, specific interactions may have no discernible effect. The chemical makeup of bioactive chemicals, medication pharmacokinetics, and individual patient characteristics such as genetics and metabolism all impact the intricacy of these interactions. Conclusions: Pharmacokinetics and pharmacodynamics of drugs can be considerably modulated through their interactions with plant bioactive components, which may cause a significant decrease in efficacy or increase in toxicity of therapeutic agents. More studies are needed to clarify mechanisms of action, prove clinical relevance, and create guidelines for safe co-administration. This integrative approach can mitigate those risks and allow for therapeutic optimization by introducing pharmacogenomics and personalized medicine approaches.

Drugs and Drug Candidates doi: 10.3390/ddc4010003

Authors: Landon E. Ebbert Tyler J. Free Mehran Soltani Bradley C. Bundy

Background/Objectives: Cancer is a leading cause of death. However, recently developed immunotherapies have shown significant promise to improve cancer treatment outcomes and survival rates. Pembrolizumab, a cancer immunotherapy drug, enables a strong T-cell response specifically targeting cancer cells to improve patient outcomes in more than 16 types of cancer. The increasing demand for pembrolizumab, the highest selling drug in 2023, increases global dependence on drug production, which can be vulnerable to supply chain disruptions. Methods: Cell-free protein synthesis (CFPS) is a rapid in vitro protein production method that could provide the production of an immunotherapy drug in an emergency and could facilitate on-demand production of the therapeutic at the point of care if needed. Furthermore, CFPS has potential as a production platform of biosimilars, as the patent for pembrolizumab is set to expire in 2028. Results: This work presents the design, synthesis, and target-binding affinity of a novel single-chain variable fragment of pembrolizumab (Pem-scFv) using CFPS. The CFPS production of Pem-scFv also enables the direct optimization of synthesis reaction composition and expression conditions. The conditions of 30 °C, 35% (v/v) cell extract, and an oxidizing redox environment resulted in the highest Pem-scFv soluble yield of 442 µg/mL. An affinity assay demonstrated significant binding between the CFPS-produced Pem-scFv and the PD-1 target. Computational simulations of Pem-scFv folding and binding corroborate the experimental results.

Drugs and Drug Candidates doi: 10.3390/ddc4010002

Authors: Jean-Jacques Hélesbeux Florence O. McCarthy Maria Manuel Silva Alcino J. Leitão Anthony Burke Jorge A. R. Salvador Rui Moreira Emília Sousa Vânia M. Moreira Pascal Marchand

The Group for the Promotion of Pharmaceutical Chemistry in Academia (GP2A) held its 32nd annual conference in August 2024 at the University of Coimbra, Portugal. There were 8 keynote presentations, 12 early career researcher oral presentations, and 34 poster presentations. Four awards were delivered, two for the best oral communications and two for the best poster presentations.

Drugs and Drug Candidates doi: 10.3390/ddc4010001

Authors: Sandra Morales Paul Hyman

Rising levels of antibiotic-resistant bacteria have led to increasing interest in the use of phage therapy as an alternative treatment. While phage therapy is conceptually simple, and numerous semi-anecdotal data suggest that it could be effective if properly managed, there have been only a few randomized, double-blind clinical trials of phage therapy so far. These trials unequivocally showed that phage therapy is safe, but there is still a paucity of data on its efficacy for managing various bacterial infections. One common response to this situation is that there is a mismatch between the regulations that govern the testing of new drugs, that is, chemical agents, and biological agents like bacteriophages. Another response has been to sidestep clinical trial testing and to use phages to treat infected patients on an individual basis, sometimes called the magistral phage approach. In this paper, we argue that regulations are not the true barrier to approval of phage therapy as drugs but rather it is the lack of efficacy data. There is no one reason behind the failures of recent clinical trials. Instead, these demonstrate the complexity of implementing a therapy where both the treatment and disease are living entities interacting within another living entity, the patient. Phage banks can have an impact by monitoring these complexities during phage therapy. Importantly, phage therapy clinical trials are continuing under existing regulatory frameworks and with products manufactured under GMP (Good Manufacturing Practices).

Drugs and Drug Candidates doi: 10.3390/ddc3040049

Authors: Olga Baturina Natalia Naumova Alexey Tupikin Elena Dmitrienko Vladimir Silnikov Marsel Kabilov

Backgound/Objective: Novel compounds for mitigating globally growing microbial resistance to antibiotics have been recently more actively researched. Triviron is a polycationic amphiphile synthetic compound with a ribonuclease activity and is used as an antiviral in veterinary medicine. Methods: We studied the effect of triviron on the mouse (line Balb/c) fecal bacteriobiome at different time points (0, 5, 25, and 120 h after a single intragastrical administration) by using amplicon sequence diversity of the V3/V4 region of 16S rRNA genes. Results: Most of the operational taxonomic units (OTUs) belonged to Bacillota (1168 OTUs, i.e., 56% of the total number of OTUs in the study) and Bacteroidota (354, i.e., 17%), with the phyla together accounting for more than 90% of the total number of sequence reads. We found changed relative abundance of some bacterial taxa with time, including the dominating Bacteroidota and Bacillota phyla; some of the changes were sex-related, although at the start of the experiment, there were no difference between the sexes in their fecal bacteriobiome composition and structure. Conclusions: The results unequivocally demonstrated that in mice, feces bacterial community structure was affected by a one-time triviron administration, even at the highest hierarchical level of phyla. The finding that the core dominant phyla can be affected, with the effect lasting at least for five days, implies that some major and important functions of the gut microbiota can be affected as well.

Drugs and Drug Candidates doi: 10.3390/ddc3040048

Authors: Karina González-García Jovito Cesar Santos-Álvarez Juan Manuel Velázquez-Enríquez Cecilia Zertuche-Martínez Edilburga Reyes-Jiménez Rafael Baltiérrez-Hoyos Verónica Rocío Vásquez-Garzón

Background: Idiopathic pulmonary fibrosis (IPF) is a chronic, disabling disorder of unknown etiology, poor prognosis, and limited therapeutic options. Previously, 3′5-dimaleamylbenzoic acid (3′5-DMBA) was shown to exert resolving effects in IPF, offering a promising alternative for treating this disease; however, the molecular mechanisms associated with this effect have not been explored. Objetive: We evaluated the potential antifibrotic mechanisms of 3′5-DMBA by network pharmacology (NP) and molecular docking (MD). Methods: 3′5-DMBA-associated targets were identified by screening in SwissTargetPrediction. IPF-associated targets were identified using lung tissue meta-analysis and public databases. Common targets were identified, and a protein–protein interaction (PPI) network was constructed; we ranked the proteins in the PPI network by topological analysis. MD validated the binding of 3′5-DMBA to the main therapeutic targets. Results: A total of 57 common targets were identified between 3′5-DMBA and IPF; caspase 8, 9, 3, and 7; myeloid leukemia-induced cell differentiation protein Mcl-1; and poly [ADP-ribose] polymerase 1 are primary targets regulating PPI networks. Functional analysis revealed that the common targets are involved in the pathological features of tissue fibrosis and primarily in the apoptotic process. MD revealed favorable interaction energies among the three main targets regulating PPI networks. Conclusions: NP results suggest that the antifibrotic effect of 3′5-DMBA is due to its regulation of the pathological features of IPF, mainly by modulating signaling pathways leading to apoptosis, suggesting its therapeutic potential to treat this disease.

Drugs and Drug Candidates doi: 10.3390/ddc3040047

Authors: Veerabhadrappa Pallavi Sathvika Prathibha Guttal Subhas Debayan Bhattacharjee Vejetha Nagaraj Koppad Uday Samrat Sindhu Bindapla Karibasappa Kadappara Mallikarjun Sagar

Background: The recurring actions and intrusive thoughts that characterise obsessive–compulsive disorder (OCD), a long-term mental illness, are known as compulsions. The cornerstones of conventional treatment are psychological counselling and prescribed medication; nonetheless, interest in complementary therapies has grown. This review looks at how well Ashwagandha, curcumin, milk thistle, valerian root, and St. John’s wort may help with OCD symptoms. Methods: To assess these herbal supplements’ potential for therapeutic benefit, case reports and clinical trials were examined. Results: Curcumin, which contains anti-inflammatory and neuroprotective properties, has shown promise in reducing the severity of OCD symptoms. Traditionally used to treat depression, St. John’s wort has shown some potential in lowering anxiety and compulsive behaviour. The herb milk thistle, which is mainly used for liver protection, did not affect OCD symptoms. Anxiolytic valerian root barely offered relief from symptoms associated with anxiety; it has only little effect on obsessions and compulsions. The adaptive Ashwagandha has demonstrated a great deal of promise in lowering stress and enhancing general well-being, which may help with symptom alleviation. Although the initial results are favourable, larger scale randomised controlled trials are necessary to validate reliability and efficacy. Conclusion: This study illustrates how herbal supplements may be used in addition to conventional medications as adjunctive treatments for OCD.

Drugs and Drug Candidates doi: 10.3390/ddc3040046

Authors: Saravanan Alamelu Kamalesh Balakumar Venkatesan Kalist Shagirtha Manoj Kumar Srinivasan Chellasamy Panneerselvam Al Thabiani Aziz Mohammed Ali Alshehri Mohamed Ali Seyed Pugalendhi Pachaiappan

Breast cancer (BC) is the most prevalent form of malignancy among women on a global scale, ranking alongside lung cancer. Presently, conventional approaches to cancer treatment include surgical procedures followed by chemotherapy or radiotherapy. Nonetheless, the efficacy of these treatments in battling BC is often compromised due to the adverse effects they inflict on healthy tissues and organs. In recent times, a range of nanoparticles (NPs) has emerged, exhibiting the potential to specifically target malignant cells while sparing normal cells and organs from harm. This has paved the way for the development of nanoparticle-mediated targeted drug delivery systems, holding great promise as a technique for addressing BC. To increase the efficacy of this new method, several nanocarriers including inorganic NPs (such as magnetic NPs, silica NPs, etc.) and organic NPs (e.g., dendrimers, liposomes, micelles, and polymeric NPs) have been used. Herein, we discuss the mechanism of NP-targeted drug delivery and the recent advancement of therapeutic strategies of organic and inorganic nanocarriers for anticancer drug delivery in BC. We also discuss the future prospects and challenges of nanoparticle-based therapies for BC.

Drugs and Drug Candidates doi: 10.3390/ddc3040045

Authors: Márcia Luana Gomes Perfeito Fábio de Oliveira Silva Ribeiro Joilson Ramos de Jesus Leiz Maria Costa Véras Alyne Rodrigues de Araújo Nobre Everton Moraes Lopes José Carlos Eloi de Queiroz Andreanne Gomes Vasconcelos Miguel Gomes Cardoso João Gonçalves Fernanda Regina de Castro Almeida Daniel Dias Rufino Arcanjo José Roberto de Souza de Almeida Leite

This work is based on research aiming to extract and identify flavonoids from jaborandi (Pilocarpus microphyllus) leaves and investigate their antioxidant and acute antinociceptive capacity. Characterization of the constituents of the ethyl acetate fraction (EtOAcF) obtained from the methanolic extract (ME) was performed by UV-Vis spectrophotometry, infrared spectroscopy, high-performance liquid chromatography (HPLC), mass spectrometry (MS), and cyclic voltammetry, demonstrating the possible majority component of this fraction, the flavone chrysin. Its solubility properties in HPLC are very close to those of the flavonol quercetin, revealing the characteristic presence of this group. An MS spectrum of the fraction revealed a major protonated molecule of m/z 254.9 [M+H]+. The EtOAcF fraction showed three oxidation processes at 0.32 V, 0.54 V, and 0.73 V vs. Ag/AgCl. Three reduction processes at the respective potentials: 0.60 V, −0.03 V, and -0.24 V vs. Ag/AgCl, indicating potential antioxidant activity. At DPPH and ABTS antioxidant radical capture assay, The IC50 obtained was 0.5 mg/mL and 0.81 mg/mL, respectively. In vivo test to determine the mechanical nociceptive threshold in the von Frey test, the dose of 100 mg/kg of the EtOAcF was able to cause inhibition of behavioral changes in neuropathy. The results obtained in this study demonstrate the biological potential of an EtOAcF derived from jaborandi leaves.

Drugs and Drug Candidates doi: 10.3390/ddc3040044

Authors: Howra Bahrulolum Parisa Beyranvand Gholamreza Ahmadian

Respiratory viruses present significant global health challenges due to their rapid evolution, efficient transmission, and zoonotic potential. These viruses primarily spread through aerosols and droplets, infecting respiratory epithelial cells and causing diseases of varying severity. While traditional intramuscular vaccines are effective in reducing severe illness and mortality, they often fail to induce sufficient mucosal immunity, thereby limiting their capacity to prevent viral transmission. Mucosal vaccines, which specifically target the respiratory tract’s mucosal surfaces, enhance the production of secretory IgA (sIgA) antibodies, neutralize pathogens, and promote the activation of tissue-resident memory B cells (BrMs) and local T cell responses, leading to more effective pathogen clearance and reduced disease severity. Bacillus subtilis spore surface display (BSSD) technology is emerging as a promising platform for the development of mucosal vaccines. By harnessing the stability and robustness of Bacillus subtilis spores to present antigens on their surface, BSSD technology offers several advantages, including enhanced stability, cost-effectiveness, and the ability to induce strong local immune responses. Furthermore, the application of BSSD technology in drug delivery systems opens new avenues for improving patient compliance and therapeutic efficacy in treating respiratory infections by directly targeting mucosal sites. This review examines the potential of BSSD technology in advancing mucosal vaccine development and explores its applications as a versatile drug delivery platform for combating respiratory viral infections.

Drugs and Drug Candidates doi: 10.3390/ddc3040043

Authors: Alba V. Demesa-Castañeda David J. Pérez César Millán-Pacheco Armando Hernández-Mendoza Rodrigo Said Razo-Hernández

Background: Staphylococcus aureus is a pathogen that has become resistant to different antibiotics, which makes it a threat to human health. Although the first penicillin-resistant strain appeared in 1945, nowadays, there are just a few alternatives to fight it. To circumvent this issue, novel approaches to develop drugs to target proteins of the bacteria cytoskeleton, essential for bacteria’s binary fission, are being developed. FtsZ and FtsA are two proteins that are key for the initial stages of binary fission. On one side, FtsZ forms a polymeric circular structure called the Z ring; meanwhile, FtsA binds to the cell membrane and then anchors to the Z ring. According to the literature, this interaction occurs within the C-terminus domain of FtsZ, which is mainly disordered. Objective: In this work, we studied the binding of FtsZ to FtsA using computational chemistry tools to identify the interactions between the two proteins to further use this information for the search of potential protein-protein binding inhibitors (PPBIs). Methods: We made a bioinformatic analysis to obtain a representative sequence of FtsZ and FtsA of Staphylococcus aureus. With this information, we built homology models of the FtsZ to carry out the molecular docking with the FtsA. Furthermore, alanine scanning was conducted to identify the key residues forming the FtsZ–FtsA complex. Finally, we used this information to generate a pharmacophore model to carry out a virtual screening approach. Results: We identified the key residues forming the FtsZ-FtsA complex as well as five molecules with high potential as PPBIs.

Drugs and Drug Candidates doi: 10.3390/ddc3040042

Authors: Ana L. Chávez-Hernández Johny R. Rodríguez-Pérez Héctor F. Cortés-Hernández Hoover A. Valencia-Sanchez Miguel Á. Chávez-Fumagalli José L. Medina-Franco

Fragment libraries have a major significance in drug discovery due to their role in de novo design and enumerating large and ultra-large compound libraries. Although several fragment libraries are commercially available, most are derived from synthetic compounds. The number of fragment libraries derived from natural products is still being determined. Still, they represent a rich source of building blocks to generate pseudo-natural products and bioactive synthetic compounds inspired by natural products. In this work, we generated and analyzed a fragment library of natural products from Colombia, a highly diverse geographical region where fragment libraries are yet to be reported. We also generated and reported fragment libraries of three novel natural product libraries and, as a reference, the most updated version of FDA-approved drugs. In line with the principles of open science, the fragment libraries developed in this study are freely available.

Drugs and Drug Candidates doi: 10.3390/ddc3040041

Authors: Janaina Fernandes

Pomolic acid (3-beta,19alpha-Dihydroxy-urs-12-en-28-oic acid, PA) is a naturally occurring pentacyclic triterpenoid. Derived from the mevalonate pathway through cyclization of 2,3-oxidosqualene, it has been widely found in several plant species. In the mid-1960s, PA was identified as the genuine aglycone of triterpenoid saponins from Sanguisorba officinalis, and studies on its biological activities began in 1989. Since then, several pharmacological properties have been described for this compound, including antitumoral activity. PA induced cell death in tumors, such as lung, brain, breast, and sensitive and resistant leukemia. Additionally, PA modulates resistant proteins and events involved in metastasis. Even though PA constitutes an important candidate for new treatment against several cancers, its availability hampers the evolution of PA studies toward clinical evaluation. This review discusses the limitations of PA availability, the recent approaches to improve it, and other aspects of the antitumoral studies on PA activity.